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ABSTRACT 
Measles virus (MeV) is considered one of the most contagious human viruses 
and has recently been declared endemic again in several countries despite a highly 
efficacious vaccine. The viral RNA dependent RNA polymerase (RdRP) is a 
heterologous complex comprised of the large protein (L), which provides all catalytic 
domains for RNA synthesis, and the phosphoprotein (P), which provides chaperone 
support for L and mediates the interaction between L and the ribonucleoprotein complex 
(RNP). Though essential for polymerase function, the interface between P and L 
remains poorly characterized, as well as the role of P in RdRP advancement along the 
RNP.  Through biochemical interface mapping, functional assays, and domain swapping 
of P, we have identified a bipartite L binding domain on P. One domain consists of a 
conserved helical motif upstream of the oligomerization domain (OD), and the second is 
a face of the P X-domain (PXD). Using stoichiometrically-controlled trans-
complementation studies and applied mathematical modeling, we also determined the 
PXD:L interaction to be mutually exclusive to the PXD:N interaction. These findings 
suggest a model that centers PXD as a master regulator of RdRP advancement. 
Rabies virus (RABV) causes a severe and 100% fatal neurological disease that 
is vaccine preventable and treatable prior to the onset of clinical symptoms. The post-
exposure prophylaxis (PEP) for RABV treatment is prohibitively expensive, especially in 
developing countries where the majority of cases occur and does not confer cross-
protection against the newly emerging phylogroup II lyssaviruses. To address the unmet 
clinical need for cross-protective anti-RABV therapeutics, we developed and 
implemented an innovative high-throughput screening approach utilizing a novel single 
cycle RABV reporter strain maintained in BSL-2 laboratory conditions. From our 
extensive screening library, we have identified the first direct-acting multi-strain RABV 
entry inhibitor, GRP-60367.  Resistance profiling of GRP-60367 revealed escape 
mutations that accelerate the fusion kinetic of the RABV glycoprotein (G). We have 
solved two of the feasibility issues with current RABV antiviral drug discovery: i) BSL-2+ 
RABV containment restraints and ii) reliable drug efficacy determination, thus paving the 
way for future drug discovery campaigns to alleviate the deficit and cost of current 
therapeutic options against lyssaviruses. 
INDEX WORDS: measles virus, rabies virus, RNA-dependent RNA polymerase, protein-protein 
interactions, antiviral, drug discovery, high-throughput screening    
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1 INTRODUCTION  
1.1 Mononegavirales Overview 
The viruses of the order Mononegavirales are characterized by enveloped virions of 
variable morphologies that shelter a linear non-segmented, negative sense RNA genome. The 
viral genome is encapsulated by nucleoprotein (N) which forms the ribonucleoprotein complex 
(RNP) [1]. The genome encodes a linear sequence of genes, with limited overlaps, and each ORF 
is divided by noncoding intergenic junctions (IGS). Each gene is expressed as an individual 
transcription unit that is bordered by short transcription start and termination sequences 
recognized by the viral RdRP. The 3¢ end of the genome contains the leader sequence that directs 
the RdRP for transcription initiation and mRNA is transcribed by sequential interrupted synthesis 
[2]. Transcription for members of Mononegavirales occurs with a gradient that results in 
decreasing expression of proteins further down the genome [3]. The viral RdRP contains an 
enzymatic capping domain that is conserved throughout the order called the GDP 
polyribonucleotidyltransferase (PRNTase). This domain caps 5¢ viral mRNA using unique 
capping mechanism that co-transcriptionally incorporates a GDP to the cap structure, which is 
then methylated at the G-N7 using the viral RdRP methyltransferase (MTase) domain [4, 5]. This 
method is in contrast to the traditional capping strategy employed by eukaryotic cells and viruses 
with positive sense RNA genomes, which utilizes the enzyme RNA 5¢ -triphosphatase (RTPase) 
for phosphate removal that results in GDP followed by transfer of a GMP moiety to the cap 
structure by guanylytransferase (GTase) [6]. The RdRP punctuates mRNA synthesis by 
adenylation of viral mRNA via iterative transcription from a short polyU tract at the end of each 
gene [1]. 
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The order of major structural proteins is highly conserved amongst members of 
Mononegavirales and include N, phosphoprotein (P), matrix protein (M), envelope proteins, and 
the large protein (L) [1]. The RNP comes pre-loaded with the viral RdRP, which consists of a 
dimeric heterocomplex of L and P.  To ensure particle assembly and budding, vital contacts are 
made by the RNP with M coating the luminal side of the viral envelope bilayer. M in turn 
interacts with the cytosolic tail of surface glycoproteins (the attachment (H), and fusion (F) 
proteins, for measles virus (MeV) or G, for rabies virus (RABV). N, P, M, envelope proteins, 
and L proteins are standard for all members of the order, though there are several viral genomes 
that encode additional proteins. For example, several viruses encode for virulence factors such as 
MeV C and V proteins, which are transcribed by leaky scanning and mRNA editing, 
respectively, RdRP processivity factors, or separation of function for attachment and fusion, e.g. 
the MeV receptor protein, H, and its fusion protein F. Of the eight families that comprise the 
viral order Mononegavirales, two of which harbor the most contagious virus, MeV, within 
Paramyxoviridae, and the most lethal virus, RABV, within in Rhabdoviridae, both of which 
continue to cause significant morbidity and mortality for humans worldwide [7, 8].   
Although efficacious vaccines exist for MeV and RABV, there are currently no drugs 
licensed for therapeutic intervention. It was the goal of the first chapter of this dissertation to 
determine the critical contacts between MeV polymerase core components (L and P).  We 
determined that the L:P interaction is bipartite. Based on this discovery, we also present a new 
model of polymerase advancement along the viral genomic template due to a dynamic 
interaction between extreme C-terminal domain of P (PXD) and L. Furthermore, due to 
conservation of the molecular architecture of the PXDs among Paramyxoviridae, we hypothesize 
that this interaction could be exploited as a potential drug target.   
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In the second chapter, this dissertation details our development and implementation of a 
novel high-throughput screening (HTS) protocol for small-molecule drug discovery against 
RABV. From our screening library of over 150,000 compounds, we identified GRP-60367 as a 
potent entry inhibitor of RABV. Discovery of this compound not only demonstrates the 
feasibility of a large-scale RABV drug discovery campaign, but further resistance profiling of 
GRP-60367 shed new light into RABV fusion kinetics. 
1.2 Chapter 1: Bipartite interface of the measles virus phosphoprotein X domain with the 
large polymerase protein regulates viral polymerase dynamics 
1.2.1 Measles Virus Disease and Treatment 
With over 100,000 deaths annually, MeV continues to be a leading cause of vaccine-
preventable morbidity and mortality for children worldwide. MeV is identified as one of the 
most infectious respiratory viruses with a basic reproduction number (R0) ranging between 12 to 
18, meaning that every infected individual has the capacity to cause 12-18 secondary cases [9]. 
As the archetypal member of the family Paramyxoviridae, MeV is a lymphotropic virus that 
spreads via nasopharyngeal droplets or airborne aerosols and clinical symptoms begin to arise 9-
19 days post-exposure. Early infection begins in the lymphoid tissue of the lower respiratory 
tract, and progressively spreads to infiltrate epithelial tissues of the upper respiratory tract [10]. 
Prodromal symptoms include fever and malaise coupled with cough, coryza, and conjunctivitis. 
Also, during the early stages of infection, white lesions on the buccal mucosa known as Koplik’s 
spots appear.  The erythematous maculopapular skin rash characteristic of clinical MeV disease 
begins several days later. It starts behind the ears, spreads to the face and eventually covers the 
rest of the body [11]. Although MeV infection is typically cleared by the patient and results in 
life-long immunity, 4-11 of every 100,000 cases can result in fatal CNS complications such as 
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acute disseminated encephalomyelitis (ADEM), measles inclusion body encephalitis (MIBE), or 
subacute sclerosing panencephalitis (SSPE) [12-15]. The late-onset SSPE occurs within 7-10 
years. A tri-residue motif within the M protein has been suggested to serve as a molecular 
determinant for SPPE because it promotes trans-synaptic migration of viral particles, though the 
exact mechanism involved remains undetermined [16]. MeV also induces immunosuppression 
up to 2-3 years post-infection, resulting in a predisposition to bacterial superinfections and 
increased risk of mortality [17].  Although there is a highly efficacious live-attenuated MeV 
vaccine readily available, there has been a global resurgence of MeV cases and within the United 
States, with over 1000 cases reported this year alone. Post-exposure prophylaxis of MeV 
infection involves vaccination, if exposure is under 72 hours, or a dose of human 
immunoglobulin (IG) within six days of exposure [18, 19]. Administration of vaccine or IG 
within the limited time window presents a challenge while cost and requirement of cold-chain for 
treatment with IG are also barriers for treatment. Another consideration is that treatment with IG 
also does not confer immunity, and, additionally, interferes with the immune response to 
vaccination [20]. For cases involving neurological complications there are no standard treatment 
protocols and typically broad-spectrum antivirals, such as IFN-a and/or ribavirin, were 
administered. However, these treatments have questionable efficacy and SSPE continues to have 
a 95% fatality rate [21-23]. The increase in cases as well as the chance of progression toward 
life-threatening neurological disease has highlighted the unmet need for MeV specific antivirals. 
Several antiviral strategies have been proposed to combat MeV infection, such as peptide 
inhibitors, natural compounds, and small-molecule inhibitors including nucleoside analogs and 
non-nucleoside analog inhibitors [21-33]. Short-chain peptide inhibitors designed to specifically 
target critical viral protein-protein interfaces (PPI) have been suggested as a potential antiviral 
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therapeutic option against MeV. Outwardly, designer peptides are a promising antiviral solution 
due to their low cytotoxicity, and high specificity to their target. Despite promising in vitro 
efficacy, advancement of peptides as a therapeutic solution remains hindered by poor oral 
bioavailability, relatively short half-life, poor membrane permeability, and the high cost of 
production [21, 33]. Natural compounds have also been extensively explored as antiviral options, 
yet they are considered to be poor candidates due to inherent cytotoxicity, high efficacious dose 
requirements, and unknown mechanisms of action [34].  
Due to its critical role in the viral life cycle, its highly conserved nature, lack of cellular 
orthologs and its multifunctional catalytic domains, the RdRP complex presents an enticing 
target for anti-viral therapy. The RdRP also engages in important PPI such as the L-P binding 
domain [35]. The only approved nucleoside analog against MeV to date remains ribavirin, a 
broad-spectrum RdRP inhibitor with reportedly poor efficacy and a plethora of adverse side-
effects [21].  Recently, a highly encouraging non-nucleoside inhibitor of the MeV RdRP, 
ERDRP-0519, has been identified and characterized as both orally bioavailable and highly 
efficacious against multiple MeV genotypes. Furthermore, drug treatment resulted in the 
generation of attenuated escape mutants. The compound showed in vivo efficacy in the closely 
related canine distemper virus (CDV)/ferret model when given prophylactically (50 mg/kg twice 
daily) with a substantial decrease in viral load and delayed lymphopenia [32]. Although, 
prophylactic treatment with the drug prolonged the lives of CDV-infected ferrets for two weeks, 
they eventually succumbed to disease resulting from a lack of proper immune stimulation. 
Animals that received the drug therapeutically mounted a strong innate and adaptive antiviral 
immune response and survived re-challenge. These studies clearly demonstrated the potential 
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antiviral impact of targeting the viral polymerase as well as demonstrated that the delicate 
balance of drug administration and immune stimulation must also be considered.  
1.2.2 MeV Lifecycle 
 
Figure 1. Measles virus lifecycle A) Schematic of genomic organization of MeV B) 
Illustrative depiction of MeV virion including Envelope (black), Attachment protein (H, light 
blue), Fusion protein (F, green), Phosphoprotein (P, yellow), Large protein (L, lavender) and 
Nucleoprotein encapsidated genome (N, orange). C) Graphic depiction of MeV replication.    
 
MeV is in the genus morbillivirus within the viral family Paramyxoviridae, which also 
houses a wide range of other clinically relevant respiratory pathogens, including mumps virus 
(MuV), the parainfluenza viruses (PIVs), and the newly emerging zoonotic Hendra (HeV), and 
Nipah (NiV) viruses. The MeV viral genome contains approximately 16,000 nucleotides and is 
encapsidated by the N protein to form the characteristic 20 nm herringbone-like RNP complex, 
all enclosed within a host-derived lipid bilayer membrane [36] (Figure 1A, B). The surface 
molecules of MeV are the tetrameric attachment protein (H), which mediates receptor binding, 
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and the trimeric type-1 fusion protein (F) [37]. The MeV H tetramer has a globular head domain 
containing the receptor binding sites, a stalk domain that is arranged in a four-helix bundle 
conformation, and four transmembrane domains [38]. F trimerization is thought to occur within 
the endoplasmic reticulum, where it is also predicted to hetero-oligomerize with H [39]. F is first 
synthesized as an F0 precursor, which is then cleaved into two distinct polypeptides, F1 and F2, 
by host-derived furin proteases during transport through the trans-golgi network  [40]. Furin 
cleavage of F loosens its interaction with H, an event that promotes F bioactivity [41]. The H:F 
complexes are expressed on the infected cell surface after traveling through the cell secretory 
pathway. Signal lymphocyte activation molecule (SLAM) and nectin-4 (N-4) are the primary 
host-cell receptors recognized by H for all wildtype MeV strains, while CD46 is only recognized 
by Edmonston and all vaccine strains derived from it [42-44]. F is maintained in a metastable 
pre-fusion state through its interaction with H. However, upon receptor binding, H undergoes 
conformational changes that result in a release of the F trimers. This release triggers the F stalk 
domains to extend and the HRA domain refolds into an extended coiled-coil to expose a 
hydrophobic fusion peptide. The fusion peptide inserts into the target membrane and forms the 
“pre-hairpin” structure. This structure begins to collapse, causing membrane curvature of both 
the viral envelope and host cell target membrane. Finally, the HRB and HRA domains form a 
stable six-helix bundle that bring the phospholipids of each membrane into close enough 
proximity that allows lipid-mixing and fusion pore formation. It is from this pore, that viral 
genetic material is released from the virion and enters the host cell. [37, 45-47]. The viral RNP 
serves as a template for cytosolic replication by the pre-assembled RdRP complex that begins 
primary transcription followed by translation of viral proteins by the host machinery. Although 
the mechanism for the switch from transcription to viral RNA replication remains unclear, excess 
8 
RNA-free N (N0) protein has been suggested as a trigger [48]. As nascent viral genomes are 
synthesized, they are concurrently encapsidated by N.  Virion assembly is orchestrated by direct 
interaction of N with M proteins, which in turn interact with the surface glycoproteins. Fully 
assembled infectious MeV virions egress in an ESCRT-independent manner [49-51] (Figure 1C).  
1.2.3 MeV Transcription and Replication 
Replication and transcription of the MeV genome is accomplished through the concerted 
cooperation between three viral proteins, N, P, and L.  The bioactive RdRP is a hetero-
oligomeric complex comprised of L and P.  L provides the enzymatic domains required for RNA 
synthesis, capping, and cap methylation, while P provides L-chaperoning support and bridges the 
interaction of L to the RNP through direct interaction with N. The RdRP can function both as 
transcriptase and replicase, though the exact mechanism for the switch between functions 
remains unknown. It has been shown, however, that an accumulation of N0P complexes 
promotes replication over transcription [48]. The viral genome contains cis-acting elements that 
provide transcription cues for the RdRP such as those for initiation, polyadenylation, and 
termination of viral mRNA synthesis. RdRP begins all transcription events at the leader sequence 
at the 3¢  end of the antigenome and progresses through the template in a continuous cycle of N-
RNA disassociation, mRNA capping, mRNA synthesis, non-templated polyadenylation followed 
by scanning through IGS for the next gene initiation sequence [52]. Re-initiation of mRNA 
synthesis is only partially efficient, resulting in an attenuation gradient that varies between IGS 
for each successive gene [48, 53]. Access of L to the template involves a dynamic interplay of 
attachment and release between the PXD and a highly conserved region that acts as a P 
molecular recognition element within the disordered tail of N (MoRE) [54]. Although the exact 
mechanism remains unknown, one predominant theory proposes that P acts as an axle to which L 
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remains fixed, while PXD proceeds in a dynamic cartwheel fashion to engage adjacent MoRE 
domains of neighboring Ns [55]. What is also unknown is the trigger resolving PXD binding to 
MoRE, since PXD and MoRE form a highly stable four-helix bundle.  
1.2.4 Viral Proteins involved in MeV RNA synthesis 
1.2.4.1 The Nucleoprotein (N) 
 
Figure 2. The Measles Nucleoprotein A) Schematic representation of MeV N 
organization B) Structure of oligomeric interactions between individual N monomers. The 
CTDarm is aqua, the NTDarm is purple and RNA is black. The CTD is in pink, and the NTD is 
yellow (PDB: 4UFT). 
 
The N protein of MeV consists of 525 residues and is divided into an N-terminal core 
domain (Ncore) (residues 1-391) and a C-terminal intrinsically disordered tail domain (Ntail) 
(residues 392-525) (Figure 2A). Ncore is further divided into two globular domains, the N-
terminal domain (NNTD) (residues 37-265) and the C-terminal domain (NCTD) (residues 266-372), 
which are linked by a short hinge region that acts as the binding cleft for the genomic viral RNA 
[56-59]. Homo-oligomerization of N is mediated by interaction of two Ncore subdomains, the 
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NNTDarm (1-36) and the NCTDarm (373-391) [60]. Recent cryo-EM structure determination of RNP 
revealed that N oligomerization occurs through the binding of an NNTDarm protomer into a groove 
of the NCTDarm of the neighboring N monomer (Figure 2B) [57, 61]. The highly disordered Ntail 
contains three highly conserved regions, called boxes 1 (400-420), 2 (489-506), and 3 (517-525) 
[59]. Ntail is also critical in the spatial organization of the Ncore protomers by ioccupying the 
space between each successive rung of the N:RNA helix. This organization causes 
approximately the first 50 residues of Ntail to be buried within the RNP helical capsid [58, 62]. It 
has also been shown that removal of Ntail increases rigidity of the N:RNA helix, causing 
decreased diameter and pitch of the total nucleocapsid structure [63]. The box 2 of Ntail is 
responsible for interacting with the PXD through an intrinsically disordered region, called 
MoRE.  Prior to PXD binding, MoRE adopts an equilibrium between partially a-helical and 
fully unfolded [64]. Mutagenesis studies performed to investigate the binding kinetics between 
PXD and MoRE have revealed that the binding affinity of the complex is finely tuned to ensure 
efficient transcription and replication [65]. Of course, mutations that completely disrupt the 
interaction abolish polymerase activity. However, those mutations that resulted in an increased 
binding affinity, such as PXDF497A, are associated with decreased transcription elongation rates 
[66, 67]. This is further supported by the observation that circulating MeV strains contain only 
substitutions of residues with the least disruptive impact on PXD-MoRE binding affinity [68]. 
Similar mutagenesis studies have determined that MoRE did not evolve to undergo 
conformational change into a-helical organization, thus resulting in some steric hindrance when 
it is induced [69]. The hindrance of a-helical induction results from a dampening effect from the 
long and disordered region of residues preceding the intrinsically disordered MoRE and further 
suggests this region as a regulatory element that promotes reiterative dissociation and association 
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of PXD with MoRE, though the exact mechanism of resolution remains unclear [70]. Although a 
popular fly-catching model has been proposed in which Ntails are required for polymerase 
recruitment and subsequent transcription, Ntail truncation studies have shown that boxes 2 and 3 
are dispensable for loading RdRP onto the template [71]. Despite activity in minigenome assays, 
an Ntail truncated recombinant virus was not able to be recovered, thus further supporting the 
hypothesis that Ntail is critical for preventing premature polymerase termination[72]. 
Furthermore, internal deletion of residues within Ntail produced viable, albeit attenuated, 
recombinant MeV and CDV viruses. This study that demonstrated that the region plays more of a 
regulatory role in transcription rather than polymerase recruitment [72]. Relocation of MoRE 
from Box 2 to Ncore resulted in restored bioactivity and recovery of recombinant virus [73]. The 
recovered virus was proficient in promoting replication and mRNA editing, yet the mutant was 
temperature sensitive and had a flattened transcription gradient. The translocation of MoRE into 
Ncore demonstrated that Ntail is required for regulating the transcription gradient, thus acting as 
a vital modulator of gene expression [73]. Not all viral families within the Order 
Mononegavirales encode a C-terminal Ntail, e.g. Rhabdoviridae and Pneumoviridae. These 
viruses mediate PXD interaction via Ncore. The evolution of Ntail may have provided newly 
emerging paramyxoviruses with enhanced N capabilities, beneficial host interactions, and an 
extra level of regulation of gene expression [73] 
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1.2.4.2 The Large Protein (L) 
 
Figure 3. The Measles Large Protein A) Schematic representation of L protein 
organization. Long regions (LR), Conserved regions (CRI, pink; CRII, orange; CRIII,yellow; 
CRIV, green; CRV, blue; CRVI, purple), Hinge regions (HR) and catalytic GDNQ motif are 
denoted. Numbers represent amino acid numbering N-terminal to C-terminal orientation. B) 
MeV homology model based on vesicular stomatitis virus (VSV) L cryoEM structure (PDB: 
5A22), colored regions depict CRI-VI and GDNQ site (magenta) surface model and ribbon form 
in 20Å resolution. 
 
Analogous to all Mononegavirales members, the MeV L is comprised of approximately 
2,200 nucleotides, and provides all of the catalytic functions required for viral RNA transcription 
and replication such as phosphodiester bond formation, mRNA capping and methylation, and 
mRNA polyadenylation. The L sequence is organized into six highly conserved regions (CRI-
VI) (Figure 3A, B). The P binding domain was determined to reside within the first 408 residues 
of L, which includes part of CRI [74, 75]. The RNA recognition site is found within CRII. CRIII 
contains the catalytic center with the GDN motif identified as essential for phosphodiester bond 
formation during viral mRNA synthesis [76]. The  L proteins of all non-segmented negative 
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sense RNA viruses, including MeV, contain a PRNTase-like domain suggesting that they share 
an unconventional capping mechanism as shown for vesicular stomatitis virus (VSV), discussed 
in Chapter 2 [4, 5]. This is in contrast to previously published data that suggest the 
paramyxovirus L protein uses GTase and RTPase activities for capping [77, 78].  Without an 
equivalent trans-capping assay to the one used to establish VSV L’s unique capping mechanism, 
we cannot definitively assign a specific capping activity to the paramyxovirus L. The L sequence 
is divided into 3 conserved long regions (LR) with variable sequences between, called hinge 
regions (HR). HRI (residues 607-650) is less tolerant of epitope tag insertion than HRII (residues 
1695-1717) suggesting less flexibility in HRI [79]. Based on these data along with in silico 
protein folding and sequence analyses, it was determined that the first 1,708 N-terminal residues 
(consisting of LR1 and LR2), which include the catalytic center along with the P and putative L 
interaction sites of the L protein, form an independent folding domain [80].  Currently, there are 
no high-resolution structural data available for any of the Paramyxoviridae L proteins. Recently, 
the structure of the L protein for respiratory syncytial virus (RSV) has been solved by cryoEM to 
a resolution of 3.2Å. Within this structure the phosphoprotein wraps around L with the C-
terminal RNP binding domain of one monomeric arm, and has a second L contact point with its 
oligomerization domain [81]. This structure was revealed one month after the findings of this 
dissertation were published; however, the structure not only bolsters our findings of a bipartite 
interface, but also suggests there is a shared molecular architecture with the RdRP complexes of 
other nonsegmented negative-sense RNA viruses as well. There is also a near atomic resolution 
(3.8Å) structure for VSV L solved by cryo-electron microscopy that includes three enzymatic 
domains (the polymerization domain, PRNTase, and MTase), and two structural domains [82]. A 
loop from the capping domain was also observed to project into the catalytic site, suggesting a 
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role in priming that is predicted to enhance fidelity and couple initiation with capping. This 
location of the priming loop also suggests dynamic changes in L confirmation after initiation that 
result in the loop receding to make room for the nascently synthesized RNA, a mechanism 
similar to the reovirus polymerase [83]. P is required by MeV L for stabilization and function, 
yet the exact location required for the interaction remains unclear. The VSV L structure was 
determined in the presence of a small N-terminal P fragment that is sufficient for inducing a 
structural initiation confirmation that promotes RdRP processivity of a non-encapsidated RNA 
template. However, the VSV P peptide was not resolved in the cryo-EM reconstruction [82, 84]. 
Although the critical residues and mechanism of P interaction with L remained unclear, it was 
suggested that the P binding domain may lie within the first 408 residues of MeV L and 
stabilizes the independently folded domains [82].  
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1.2.4.3 The Phosphoprotein (P) 
 
Figure 4. The Measles Phosphoprotein A) Schematic representation of P protein 
organization. The N-terminal region of P (PNTD, yellow), C-terminal region of P (PCTD), 
oligomerization domain (OD, green), and the extreme C-terminal domain (XD, blue) are 
annotated by residue numbering. Residues 361-377 within the OD are dark green. B) ODs of 
closely related paramyxoviruses: MeV (green, PDB: 4ZDO), MuV (purple, PDB: 4EIJ), Sendai 
virus (pink, SeV, PDB: 1EZJ), NiV (yellow, PDB: 6EB9) C) Diagram depicting critical residue 
interactions with PXD, either with MoRE (left), or the hydrophobic contacts within the PXD 
bundle (right). The MoRE helix is depicted as yellow, and the PXD is colored blue. (PDB: 1T60) 
D) Summary depiction of current knowledge of the L binding site for several members of 
Mononegavirales. 
 
MeV P, though catalytically inactive, is an essential RdRP cofactor that provides a 
diverse repertoire of functions critical for viral replication and transcription. These functions 
include sequestering soluble monomeric RNA-free N (N0) to prevent unintentional encapsidation 
of host cell mRNAs, L chaperoning support, and promotion of RNA synthesis by bridging the 
interaction between L and the RNA template [54]. Reflecting its multifunctional nature, P is a 
modular protein organized into three distinct and highly conserved domains that are separated by 
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long disordered regions: the N0 binding domain (PNBD, a.a. 1-40), the oligomerization domain 
(OD, a.a. 303-373), and PXD (a.a. 459-507) (Figure 4A) [85-87]. The N-terminal residues 1-48 
have been previously mapped as the N0 binding region found to be highly conserved among 
members of the Mononegavirales [88]. Recent high-resolution crystallographic data has 
unveiled that the molecular mechanism of P interaction with the Ncore occurs through 
hydrophobic coiled-coil interactions with two adjacent N protomer arms. The resulting steric 
hindrance is predicted to prevent N protomer oligomerization [56]. These interactions are also 
presumed to induce a conformational change that lowers RNA binding affinity. For the 
paramyxovirus, Nipah virus (NiV), a similar mechanism of NTarm interaction was uncovered.  
However, it was proposed to interfere with the molecular opening and closing switch of N0, thus 
rigidifying the NiV P in an open conformation [89]. This mechanism contrasts with that of VSV 
P, however, since part of the N-terminal region of VSV P extends into the N protomer arm 
binding cavity and a small helical region binds the hinge region between NCTD and NNTD, thereby 
extending into the RNA-binding groove [90]. Although the crystal structure of the MeV N0P 
complex provides insight into the chaperoning function of P, the mechanism of release of N0 and 
subsequent encapsidation of newly synthesized viral genomes still remains poorly understood. 
Self-association of P is highly conserved among all members of the Mononegavirales.  
Early predictive modeling of P OD identified heptad repeats spanning residues 303-375. The 
coiled-coil multimerization domain was later confirmed through X-ray crystallography. The 
crystal structure of MeV P OD revealed it to be a coiled-coil parallel homo-tetramer that features 
a tightly packed hydrophobic interface and kinked helices [86]. This finding was in contrast to 
the recently solved Sendai virus (SeV) P OD, which has a hollow hydrophilic interface and is 
capped by an N-terminal helical bundle [91]. The crystal structure of MeV P OD and those of 
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several other paramyxoviruses, e.g. NiV and mumps virus (MuV), exhibit a central kink in the 
three-dimensional structure due to a break in the heptad repeat (Figure 4B) [92]. In the case of 
MeV, this break is due to a stammer of leucine repeats that induce the coiled-coils to adopt a 310 
a-helical conformation. The role of the kink has recently been identified as a regulatory element 
for viral gene expression [93]. Interestingly, a short disordered section within the C-terminal 
region of the P OD consisting of residues 361-375 was identified through comparison of two 
contrasting solved crystal structures of P [94]. Recent studies have further implicated these 
residues as crucial for L structural stabilization in addition to promoting RdRP bioactivity [93] 
Bridging of the polymerase complex to the viral genomic template is orchestrated by the 
direct interaction of PXD with MoRE. Recent structural characterization of PXD revealed it to 
be a globular domain organized into three antiparallel a-helices that are held together primarily 
by hydrophobic intermolecular interactions [87]. The association of MoRE with PXD 
implements an association-induced folding by the induction of a local a-helical fold of MoRE to 
form a hetero-four-helix bundle that principally relies on hydrophobic contacts within the large 
hydrophobic cleft between the a-2/a-3 face of the triangular PXD prism [65] (Figure 4C). The 
PXD-MoRE complex is assembled in a 1:1 stoichiometry and has an equilibrium dissociation 
constant (KD) of about 3.1 µM [67]. A complex hydrogen bonding network governs the PXD-
MoRE interaction; specifically, association between residues S491 within MoRE and L489 and 
N493 on PXD reportedly has the most impact on binding [67, 95-97]. Residue F497 within a3 
on PXD was also recognized as a critical residue for intermolecular hydrophobic interactions 
with residues I464, I468, L481, I488, and L501 of PXD that stabilize the a-helical bundle 
scaffold that promotes MoRE binding without direct interaction (Figure 4C) [98]. Furthermore, 
the folding pathway between native, intermediate, and bound states of PXD to MoRE has been 
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characterized and shows varying levels of compaction, presumably reflecting a necessity to 
negotiate association and dissociation with MoRE.  
P interacts directly with L to stabilize its native conformation and to mediate physical 
interaction of the RdRP with the viral genome. Though the L:P interaction is essential for viral 
transcription and replication, the mode of contact between the two proteins is poorly 
characterized. Early MeV P mapping studies using co-immunoprecipitation (coIP) and yeast-2-
hybrid (Y2H) analyses of truncated P fragments determined that PNT does not harbor the L 
binding domain [99]. The rinderpest virus (RPV) L binding domain on P was investigated with 
C-terminally truncated P fragments using Y2H assays. This study resulted in the proposal that 
the interface comprises the entire P C-terminus (PCT) including the OD [100]. This finding was 
bolstered by data obtained using the construction of chimeras consisting of swapped 
morbillivirus PCT domains between rinderpest virus (RPV) and pestes-des-petites-ruminants 
virus (PPRV) that showed they were still able to form heterologous complexes with the RPV L 
(Figure 4D) [101]. This discovery inferred that shared residues among members of the genus 
either govern the interaction, or that the interaction is based on a similar molecular architecture 
conserved across morbilliviruses. Inclusion of the OD within the L binding interface also 
suggests either a requirement of higher oligomeric order, or that highly conserved residues are 
involved in the L binding interface. Interestingly, the OD also has several charged residues 
within its coiled-coil interface. It also contains a stretch of leucines that alter the helical structure 
resulting in a kink at residue L342.  This kink was suggested by Communie, et al. to act as a 
platform for a binding partner such as L [86]. Replacement of the OD with the tetramerization 
domain of GCN4 revealed that this kink is dispensable for L interaction, albeit required for 
bioactivity [92]. Highly conserved residues within the extreme C-terminal region of the OD were 
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found to be essential for L stability, hinting at a role in binding of L, either directly or indirectly 
[93]. P is furthermore critical for recruitment of host heatshock protein 90 (HSP90) chaperones 
that mediate proper folding and solubilization of functional L proteins and the subsequent 
formation of mature and stable L-P complexes [102]. Though required for maturation of the core 
RdRP complex, HSP90 is dispensable for bioactivity [102]. The recruitment of HSP90 for 
chaperoning support has been confirmed for various mononegaviruses including, besides MeV, 
VSV and NiV. However, the location and purpose of the HSP90 interaction with P has yet to be 
determined [102-105] .   
1.2.5 Aim of Dissertation Chapter 1 
The overarching aim of Chapter 1 is to disclose critical elements involved in the L:P 
interaction, as well as to disclose how the L:P heterocomplex negotiates the viral template 
through its interaction with MoRE.  
The first aim of this study was to characterize and identify critical molecular 
determinants for L:P interaction. This was accomplished via mutational analysis, alanine 
scanning, terminal and internal truncations in combination with co-immunoprecipitation studies. 
Critical residues for L:P binding were confirmed by minireplicon bioactivity studies, and 
biological relevance was tested by recovery of recombinant viruses. 
The second aim of this study was to identify the molecular stoichiometry of MoRE:P:L 
that is required for RdRP processivity. The stoichiometric ratio of the P:L interaction was 
determined by trans-complementation of P mutants deficient for L interaction. Secondly, 
determination of whether the L:P interaction is mutually exclusive to P:MoRE was determined 
by trans-complementation between P:L and P:MoRE deficient mutants and tested through co-
immunoprecipitation as well as minireplicon bioactivity assays.  
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1.2.6 Chapter 1 Materials and Methods 
Cell culture: Baby hamster kidney cells (C-13; ATCC) stably expressing T7 polymerase 
(BSR-T7/5), African green monkey kidney epithelial (Vero) cells (CCK-81; ATCC), and Vero 
cells stably expressing human signaling lymphocytic activation molecule (Vero-hSLAM) were 
maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 7.5% fetal 
bovine serum at 37°C and 5% CO2 . The stable cell lines were incubated in the presence of G418 
(Thermo-Fisher) (100 µg/ml) at every fifth passage. Cells were transiently transfected using 
GeneJuice (Novagen) according to the manufacturer’s instructions.  
Molecular biology: Codon-optimized open reading frames encoding MeV IC-B-derived 
L, L1708, and P were synthesized in vitro (GeneWiz). The PDOD variant lacking residues 303-360 
was generated through PCR amplification and re-ligation at an added HindIII site. Yeast-derived 
GCN4 tetramerization domain was PCR amplified from a previously generated template [47] and 
inserted using the HindIII site. All alanine substitutions and amino acid changes were performed 
by site-directed PCR mutagenesis using the QuikChange protocol (Stratagene). C-terminal 
truncations were performed by PCR mutagenesis and subsequent religation at an added AgeI 
site. Plasmids encoding the MeV minireplicon luciferase reporter, non-optimized MeV IC-B N, 
IC-B P, and IC-B L under T7 promoter control, and a full-length cDNA copy of the MeV IC-B 
genome were previously described [106]. A full-length cDNA of recMeV IC-B expressing P-
V463R and P (361-364)Ala in tandem was generated based on non-codon optimized mutant 
versions of IC-B P using the NEBuilder® HiFi DNA Assembly kit, introducing an artificial 
intergenic sequence (IGS) between the two P copies. The assembled recMeV IC-B P-V463R-N-
IGS-P (361-364)Ala cassette was transferred to the full-length genomic plasmid between the N-P 
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and P-M intergenic junctions using existing XbaI and SalI restriction sites. Mutagenesis success 
and the integrity of all PCR-amplified nucleic acids was confirmed through Sanger sequencing.  
SDS-PAGE, immunoblotting and densitometric quantitations: Cells were transfected 
in a 6-well plate format (5 x 105 cells/well) with 1 µg of plasmid DNA encoding codon-
optimized MeV L1708 with a C-terminal FLAG epitope tag and 1.8 µg of plasmid DNA encoding 
MeV P or P mutants, each with a C-terminal HA epitope tag. After 36 hours, cells were washed 
two times with phosphate buffered saline (PBS) and lysed chemically (50 mM HEPES (pH 7.2), 
300 mM NaCl, 1.0 mM EDTA, 1% Triton X-100, protease inhibitors (Roche)). Cleared (10-
minute centrifugation at 12,000 rpm, 4°C) lysates were mixed with 5´urea buffer (200 mM 
Tris/Cl [pH 6.8], 8 M urea, 5% SDS, 0.1 mM EDTA, 0.03% bromophenol blue, 1.5% 
dithiothreitol). Samples were incubated for 30 minutes at 50°C and separated on 8% SDS-PAGE 
gels, tank-blotted on polyvinylidene difluoride (PVDF) membranes (Millipore), and subjected to 
chemiluminescence detection using specific antibodies directed against the FLAG (M2; Sigma) 
or HA (16B12; Abcam) epitopes, MeV N (clone 83KKII; Millipore Sigma), or against cellular 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 6C; Ambion) as specified. Immunoblots 
were developed using a ChemiDoc digital imaging system (Bio-Rad) for image visualization. 
Densitometry was carried out on non-saturated images with global background correction. A full 
set of positive (wild type P) and negative (equivalent amount of vector DNA replacing P-
encoding plasmid DNA) controls were included on each immunoblot, and no normalizations 
across different blots were conducted.   
Native-PAGE: Cells transfected with 1.0 µg MeV P or P mutant-encoding plasmid DNA 
were harvested after 36 hours as specified above. Cleared lysates were mixed with 1 µl G-250 
sample additive (Invitrogen) and 4´Native-PAGE sample buffer (Invitrogen). Electrophoretic gel 
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fractionation was carried out using 3-12% Bis-Tris gradient gels (Invitrogen) and NativePAGE 
running buffer. Immunoblotting and detection were performed as outlined above.  
Co-immunoprecipitation: Cells (5 x 105 cells/well) were transfected with MeV L1708 
and P or P mutant-encoding plasmid DNA as detailed above. Cells were lysed 24 hours after 
transfection and cleared lysates incubated with specific antibodies directed against HA or HIS 
epitopes (HIS.H8; Invitrogen; only for immunodetection after trans-complementation; Figure 
5A), or against MeV N (only for immunoprecipitations in Figure 4D) at 4°C, followed by 
precipitation of immunocomplexes with immobilized protein G (Pierce) in 50 µl bed volume at 
4°C. G-protein bound protein samples were washed twice each in cold lysis buffer and PBS, 
each wash with 20 bed volume equivalents (1 ml), followed by resuspension in 5x urea buffer. 
Denatured samples were subjected to SDS-PAGE analysis using 8% homogenous gels followed 
by immunoblotting and detection using specific antibodies directed respectively against the 
FLAG, HA, or HIS epitopes as described. To calculate relative co-immunoprecipitation 
efficiencies, densitometric quantitations of co-precipitated L were normalized for those of L co-
precipitated by standard P. This approach is based on the rationale that although L turnover rates 
are increased in the absence of P or presence of L binding-incompetent P mutants, synthesis rates 
of plasmid-encoded L is independent of P and standard and mutant P have therefore equal initial 
opportunity to productively interact with nascent L polypeptides. 
Minireplicon reporter assay: BSR-T7/5 cells (5,000 cells/well in a 96-well plate 
format) were transfected in nine technical replicates per condition assessed with plasmids 
encoding MeV IC-B L (0.02 µg), IC-B N (0.016 µg), the MeV luciferase replicon reporter (0.044 
µg), and either IC-B P or P mutants as specified (0.02 µg unless stated otherwise in Figure 
captions). In all experiments that involved transfecting variable amounts of mutant and wild type 
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P-encoding plasmid DNA ratios, empty vector (pUC-19) DNA was added in the appropriate 
amounts to ensure that all transfection reactions received the same total amount of DNA. Firefly 
luciferase activities were determined 24 hours post-transfection in a Synergy H1 microplate 
reader (BioTek), using Bright-Glo luciferase substrate (Promega) directly added to the wells and 
signal detection after a 1 to 2-minute stabilization period. Relative RdRP activities, expressed as 
percentages of that observed in the presence of wild type P, were determined according to the 
formula % rel. activity = (signalsample-signalmin)/(signalmax-signalmin) ´ 100, with signalmax 
corresponding to cells having received wild type P and signalmin corresponding to cells having 
received equal amounts of pUC-19 in place of P-encoding plasmid. Results calculated for each 
biological repeat represent the means of the nine technical repeats, and each condition (P mutant, 
competition or trans-complementation setting) was assessed in at least three biological repeats.  
Recovery of recombinant MeV: recMeV were recovered by transfection of BSR-T7/5 
cells with full-length antigenomic plasmid (1.25 µg) and the plasmids encoding IC-B N (0.42 
µg), IC-B-P (0.54 µg), and IC-B-L (0.55 µg). Transfected cells were overlaid after 48 hours onto 
Vero-hSLAM cells. Emerging infectious centers were individually transferred to and then 
passaged twice on Vero-hSLAM cells, followed by whole RNA extraction from infected cells 
(RNeasy kit; Qiagen), first strand synthesis using random hexamer primers and Superscript III 
reverse transcriptase (Invitrogen), PCR amplification of synthesized cDNAs using appropriate 
primers, and Sanger sequencing. Titers of MeV stocks were determined through TCID50 titration 
on Vero-hSLAM cells as described [107].  
Viral growth kinetics: Vero-hSLAM cells were plated in 12-well format (1.0´105 cells/ 
well) and infected with recovered viruses, either recMeV IC-B or recMeV IC-B P-V463R-P 
(361-364)Ala at a multiplicity of infection (MOI) 0.01 TCID50 units per cell for 1-hour, followed 
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by replacing the inoculum with growth media. To ensure accurate inoculum concentrations, virus 
stocks were pre-diluted to approximately 5,000 TCID50/ml and inoculum titers validated through 
TCID50 titration. Cell-associated viral particles were harvested in 12-hours intervals through 
scraping of cells in serum-free DMEM, two consecutive freeze/thaw cycles, and clearance 
centrifugation (2,000 rpm, 4°C). Viral titers in cleared samples were determined through TCID50 
titration.  
Photometric CPE quantitation: Vero-hSLAM cells were plated in a 12-well format 
(1.0´105 cells/well) and infected with either recMeV IC-B or recMeV IC-B P-V463R-P (361-
364)Ala at a MOI of 0.01 TCID50/cell for one hour, then inoculum was replaced with growth 
media. Infected cells were imaged in 2-hour increments over a period of 36 hours post-infection 
with a Cytation5 automated high content imager with phase contrast microscopy capacity 
(BioTek). The increase in µm2 area size covered by individual infectious centers first detected at 
24 hours after infection was quantified over time using the Gen5 microplate software program 
(Ver. 3.05.11) (BioTek). A maximum of four syncytia/well were followed, quantitations are 
based on 10 distinct syncytia/virus analyzed. CPE kinetics are expressed as fold-change of area 
size relative to the 24-hour after infection timepoint. 
Mathematical models of bioactivity: Based on behavior in native-PAGE, mutant and wild type 
P co-expressed in the same cell were given equal probability to tetramerize and the mutant 
occupation of one P monomer was treated independent of the other three monomers. The ratio 
between mutant (Mx) and wild type (wt) P was denoted as ρ. Adapting a previous approach to a 
comparable problem [108], the probabilities of the formation of tetramers with different 
compositions were calculated as follows:   
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A number of interactions of host proteins with MeV P and N have been proposed [109], but very limited 
insight into this complex interactome precludes integration into rational modeling. We therefore applied a 
deconstruction approach, concentrating on individual point mutations affecting specific interactions 
between P-XD and L or N-MoRE, respectively. At any given mutant to wild type P ratio ρ, all five 
different P tetramer compositions will be present in the system (illustrated in Figure 7D). Two hypotheses 
regarding the bioactivities of these tetramer species were examined. In both models, the a-values reflect 
the individual contribution of each of the different P tetramer assemblies to overall bioactivity, with 
consideration of the relative abundance of each assembly in the system.   
i) Linear combination: all tetramers with at least one wild type P monomer is bioactive and their 
contributions to RdRP bioactivity (A) are linearly additive: 
𝐴 =2 𝛼4𝑃4#$
"
45'
= 𝛼6𝑃6#$"- + 𝛼'𝑃'#$,- + 𝛼/𝑃/#$/- + 𝛼,𝑃,#$'- + 𝛼"𝑃"#$6-	 
Assumptions made: all-mutant P tetramers (P0wt4M) are bio-inactive (Figures 7C, 10, 
12E), 𝛼6 = 0. Therefore, only four weights needed to be fitted; positive weights reflect positive 
and negative weights negative contributions to overall bioactivity; tetramer species with a weight 
of 0 are bio-inactive.  
ii) Non-linear pairwise P-XD competition: in addition to each tetramer species potentially 
contributing to bioactivity, a possible impact of competition for binding sites was considered:  
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Assumptions made: all-mutant P tetramers (P0wt4M) are bio-inactive (Figures 8E, 12A, 
12C); all four P-XDs within a P tetramer function independently of each other; bioactivity 
requires XD binding to L and MoRE; both wild type and mutant XDs are equally MoRE binding 
competent (Figure 8B); the V463R mutation selectively impairs XD interaction with L only; and 
a single L binding-competent XD in the P tetramer is necessary and sufficient for bioactivity of 
the RdRP complex (Figures 12B-3 and 12D-1).  
Data fitting: Experimental measurements of relative RdRP bioactivities were fitted to the above 
models using lsqcurvefit, a nonlinear regression model in Optimication Toolbox of MATLAB 
R2017a (MathWorks). Goodness of fit was calculated using R2 values, defined as the proportion 
of the variance in the dependent variable that is predicable from the independent variables. 
Activity data sets for P (361-364)Ala  and P-V463R were assigned a default bioactivity data point 
A = 1 when ρ = 0. 
 
Statistical analyses: One or two-way ANOVA with Tukey’s post-hoc multiple 
comparisons tests or T-tests were used to assess statistical difference between samples, in all 
cases using the Prism 8 software package (Graph Pad). The nature of individual statistical tests 
applied is specified in each Figure legend, p value-intervals are shown. Wherever possible, 
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graphical representations of experimental results show both the means of all biological replicates 
± standard deviations (SDs) and individual biological repeats. All experiments were carried out 
in at least three biological repeats. 
1.2.7 Chapter 1 Results 
To dissect the contribution of individual MeV PCT domains to L binding, we first focused 
on OD. In MeV P expression plasmids, we either deleted this domain by removing residues 303-
360 (OD structure up to residue 360 was resolved in [110]) or replaced this section up to residue 
360 or 377 (end of defined heptad repeat motif), respectively, with the tetrameric mutant of the 
yeast general control protein 4 (GCN4) coiled-coil [111] (Figure 5B). The effect of these 
modifications on the physical interaction of P with L was assessed through co-
immunoprecipitation (co-IP) of the proteins from the lysates of transiently transfected cells. All 
co-IPs were carried out with a C-terminally truncated form of L, L1708 lacking the L 
methyltransferase domain, that we have previously shown to be fully folding competent and 
capable of forming bioactive polymerase complexes when post-translationally combined with the 
corresponding C-terminal L fragment [80]. Co-IP efficiencies of L1708 or full-length L with P are 
indistinguishable (Figure 6), but L1708 facilitates biochemical analysis of P-to-L binding due to a 
lower tendency to self-aggregate spontaneously [74].  
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Figure 5. P OD C-terminal microdomain is required for P-to-L binding A) Overview of 
proposed L binding domains on P for different Paramyxoviridae. Numbering refers to MeV P. B) 
Schematic representation of P with OD deletion or exchange with yeast GCN4. C) Immunoblots 
of whole cell lysates (WCL) and immunoprecipitates (IP) after co-transfection with L1708 (L) and 
P variants shown in (B). P was detected with anti-HA antibodies, L with anti-FLAG antibodies. 
GAPDH served as loading control. Graph shows relative co-IP efficiency of L with P; columns 
are means ± SD, symbols show individual biological repeats (n = 3). D) Native PAGE analysis 
of P constructs shown in (B). Trimeric and dimeric variants of yeast GCN4 (P-GCN4Trimeric and 
P-GCN4Dimeric, respectively) were included for mobility reference. SDS-PAGE shows 
immunoblots of the identical samples after denaturation and reduction. E) P-L co-IP of alanine 
scanning mutagenesis of the P (361-377) microdomain. F) Monocistronic minireplicon assay 
performed in the presence of wild type P or P mutants specified. Columns are means ± SD, 
symbols show individual biological repeats (n = 3). All statistical analyses through one-way 
ANOVA with Tukey’s post hoc multiple comparison test. (NS, not significant; **, p ≤ 0.01; ****: 
p ≤ 0.0001). 
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Figure 6. Full-length L and truncated L1708 interact with P with equal efficiency. 
Cartoons provide a schematic overview of the L constructs. Numbers refer to amino acids. 
Immunoblots of input and co-precipitated material assessing P interaction with full-length and 
truncated L. Detection and quantitative analysis as in Figure 1C. Columns show means ± SD, 
symbols represent individual biological repeats (n = 3). Statistical analysis through unpaired T-
test (NS, not significant). 
 
1.2.7.1 MeV P residues proximal to the structurally defined OD are critical for L interaction 
When subjected to this assay, the PDOD mutant lacking the oligomerization domain was 
unable to co-precipitate L (Figure 5C). In contrast, efficient wild type P-equivalent L binding 
was maintained when P OD up to residue 360 was replaced with yeast GCN4 (P-GCN4303-360). 
Further extension of the GCN4-substituted area up to P residue 377 eliminated any appreciable 
interaction with L. Native-PAGE analysis confirmed that both GCN4-substituted P mutants 
tetramerized efficiently, whereas PDOD predictably remained monomeric (Figure 5D). In 
contrast to previous theories [86, 92, 99], residues in the MeV P OD core do not, therefore, form 
a physical interface with L but contribute to the interaction only indirectly through the initiation 
of mandatory P tetramerization. However, residues in the short stretch at the OD C-terminus 
from position 361 to 377 are candidates for direct L binding.   
Alanine-scanning mutagenesis of the 361-377 microdomain revealed that all sub-sections 
tested are required for efficient L binding (Figure 5E). Although reductions in L co-IP efficiency 
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were statistically equivalent, we noted the lowest relative interaction with L when P residues 
361-364 were substituted with alanines, creating P (361-364)Ala. Employing a mono-cistronic 
firefly luciferase MeV minireplicon reporter system that we have previously described [73], we 
assessed bioactivity of the different alanine mutants after co-expression with unmodified, 
homotypic MeV N and L proteins. Consistent with impaired physical interaction of these P 
mutants with L, all four constructs abolished RdRP bioactivity (Figure 5F). Despite its unaltered 
physical interaction with L, P-GCN4303-360 also lacked bioactivity in minireplicon assays, 
indicating that the P OD has a role in viral RdRP activity distinct from L binding and mediating 
P tetramerization.  
1.2.7.2 Substitutions in the P OD C-terminal microdomain are dominant-negative to RdRP 
bioactivity 
Residues in the P OD section 361-377 follow a 3-4 heptad repeat pattern that is 
characteristic for a-helical coiled-coils and conserved across pathogens of the morbillivirus 
genus (Figure 7A). To increase resolution of the alanine scan, we followed up with pairwise and 
individual substitutions in the 361-364 microdomain that had shown the strongest disruption of 
co-IP efficiency. This biochemical assessment demonstrated that disruption of P interaction with 
L was equally carried by residues 363 and 364, although the quadruple substitution still returned 
the most robust effect on average (Figure 7B). Independent of residual L binding capacity, all 
single and tandem substitutions except S361A eliminated RdRP bioactivity in minireplicon 
assays (Figure 7C).  
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Figure 7. P (361-364)Ala acts on RdRP bioactivity in a dominant-negative manner A) 
Alignment of P residues 361-377 of selected morbilliviruses. Predicted a and d positions of 
heptad repeat motif are highlighted. B) P:L interaction analysis of P mutants with alanine 
substitutions at positions 361-364. Detection and quantitative analysis as in Figure 1C (n ³ 3). 
C) Minireplicon assay with P alanine substitutions at positions 361-344 (n = 3). D) Schematic of 
mixed P tetramer species present after co-expression of P (361-364)Ala (M1) and wild type P (wt). 
Equations specify the probability of formation for each tetramer species, and the graph shows 
the relative proportion of these species in co-transfected cells as a function of wild type and 
mutant input plasmid ratio, graphically represented below the x-axis. E) Observed RdRP activity 
in minireplicon assays in the presence of different P (361-364)Ala and wt P ratios as depicted in 
(D). Symbols show means of experimentally observed biological repeats ± SD (n = 3). Solid lines 
represent activity curve predictions according to a linear combination model and the relative 
distributions of the P tetramer species shown in (D). The dotted line (red) represents the best fit 
curve of the experimental data with weight assignments specified in the equation (A, relative 
RdRP activity), goodness of fit (R2) is indicated. All statistical analyses and symbols as detailed 
in Figure 5. 
 
32 
Structural analysis has revealed that some helices of the P-OD coiled-coil extend to residue 
373 [86]. Combined with an intact heptad repeat pattern up to residue 377, assembly of the entire 
361-377 stretch into an extended coiled-coil and interaction with L as a tetrameric assembly 
appears likely. To test whether the P (361-364)Ala substitution has a cooperative effect on P 
tetramer activity, we generated competition profiles of mixed P tetramers by gradually increasing 
the relative amount of mutant P in minireplicon assays in the presence of a constant, low level of 
wild type P. Under these conditions, five distinct P tetramer species will form in all co-
transfected cells, with the relative species distribution determined by the input ratio of mutant 
and wild type P-encoding plasmid DNA (Figure 7D), since native-PAGE analysis confirmed 
that the 361-364 alanine substitution did not affect the ability of P to tetramerize (Figure 8). 
Minireplicon-based assessment of RdRP bioactivity in the different cell populations revealed a 
steep decline in minireplicon expression in the presence of increasing amounts of the P (361-
364)Ala mutant (Figure 7E). This decline was not simply due to increasingly unfavorable ratios 
of P- versus N- and L-encoding plasmid transfected. When we generated P plasmid 
concentration-activity profiles, relative activities followed an optimum curve, but activity 
differences were statistically not-significant over the plasmid ratio range explored in the 
minigenome competition profile (Figure 9).  
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Figure 8. Native PAGE analysis of P (361-364)Ala and respectively denatured and 
native wild type P.  SDS-PAGE shows immunoblots of the identical samples after denaturation 
and reduction. 
 
 
 
Figure 9.  RdRP minireplicon activity profile describing the effect of different relative 
amounts of wild type P-encoding plasmid DNA transfected. Amounts of plasmids encoding L and 
N were kept constant. Symbols show means of experimentally observed biological repeats ± SD 
(n = 3). Statistical analyses through one-way ANOVA with Dunnett’s multiple comparison test, 
relative to starting conditions (0.1 µg); (NS, not significant). 
 
We tested a series of mathematical models for the best description of the experimental 
competition data. Assigning all mutant and wild type P proteins co-expressed in the same cell 
equal probability to tetramerize, we considered the mutant occupation of one P monomer to be 
independent of the other three monomers. Goodness of fit was excellent (R2 = 0.96) for a linear 
combination model in which only tetramers consisting of four wild type (4´wt) or three wild 
type and one mutant (3´wt/1´P (361-364)Ala) P monomers contribute to RdRP bioactivity, while 
all other P tetramer species are biologically inactive (Figure 7E). These results indicate that at 
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most one P (361-364)Ala monomer can be present in a partially bioactive P tetramer, revealed a 
dominant-negative effect of the P (361-364)Ala mutation that we consider to be due to 
interference with coiled-coil extension.  
1.2.7.3 P-XD is an essential contributor to efficient P interaction with L 
The C-terminal 50 residues of P form the XD, which has been shown biochemically and 
crystallographically to mediate binding of the polymerase complex to the RNP through 
interaction with the MoREs located near the end of each N-tail [96, 98, 112]. To confirm that P-
XD has a direct role in L binding, we generated a series of mutants with C-terminal truncations 
of gradually increasing length (Figure 10A). Co-IP analyses identified an essential function of P-
XD in mediating efficient interaction with L (Figure 10B), since even partial shortening of P-
XD was sufficient to cause significant reduction in co-IP efficiency and larger truncations 
abolished all appreciable interaction between P and L. Consistent with a dual role of P-XD in 
both MoRE and L binding, all C-terminal P truncation mutants lacked bioactivity in minireplicon 
assays (Figure 11). When we co-expressed isolated P-XDs – either in the form of individual 
polypeptides or as fusion proteins with GST for stabilization – with L, however, no biochemical 
interaction could be detected (Figure 10C). We conclude that P-XD is an essential contributor to 
efficient P-to-L binding. Unlike the strong interaction of P-XD with MoRE affording efficient 
co-immunoprecipitation [106], the affinity of isolated P-XD polypeptides for L is low, 
suggesting that isolated P-XDs are folding compromised, or P-XD does not share a direct 
interface with L.  
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Figure 10. P-XD is essential for efficient P:L interaction, but P-XD deletion mutants lack 
cooperative negative impact on RdRP activity . A) Schematic of P mutants generated with C-
terminal truncations. B, C) P:L interaction analysis of P mutants shown in (A) and P-XD 
expressed in isolation (P-XD) or as a GST fusion protein (GST-P-XD). Detection and 
quantitative analysis as in Figure 1C (n ³4 (B) and n = 3 (C)). D) Observed RdRP activity in 
minireplicon assays in the presence of different PDXD (M2) and wt P ratios as graphically 
depicted below the graph. Symbols with connecting line represent means of experimentally 
observed biological repeats ± SD (n = 3). Solid lines represent activity curve predictions 
according to a linear combination model as in Figure 2E. All statistical analyses and symbols as 
detailed in Figure 1 (*, p ≤ 0.05).  
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Figure 11. Minireplicon analysis of bioactivity of the C-terminally truncated P mutants 
depicted in Figure 3A. Columns represent mean relative RdRP activities, symbols show 
individual biological repeats ± SD (n = 3). Statistical analyses through one-way ANOVA and 
Tukey’s multiple comparison test (NS, not significant; ****, p ≤ 0.0001). 
 
To explore the minimal stoichiometry of intact XDs per P tetramer that is required for 
bioactivity, we again co-expressed increasing relative amounts of the PDXD mutant with wild 
type P in minireplicon competition assays. The resulting activity profile was notably distinct 
from that obtained with the P (361-364)Ala substitution (Figure 10D). Even at the highest relative 
ratios (up to 10) of the PDXD mutant, RdRP activity remained significantly higher than 
background, indicating that PDXD has no dominant-negative effect, and lower relative ratios of 
the PDXD unexpectedly resulted in a significant boost in RdRP activity compared to that 
observed in the presence of wild type P only.  
Modeling attempts revealed that these data could not be described with a weighted linear 
combination function. We, therefore, explored several non-linear models, but the complex 
biology of P-XD prevented a satisfying mathematical representation of the experimental results 
without overfitting the data set. While our results thus reveal that partially reducing the number 
of L and MoRE binding-competent XDs within a P tetramer boosts overall RdRP bioactivity, 
meaningful mathematical modeling of the phenotype requires a better-targeted approach than 
removal of P-XD entirely. We, therefore, explored the mapping of the P-XD interface contacting 
L. 
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1.2.7.4 Distinct faces of the P-XD triangular prism mediate binding to MoRE and L  
In co-crystals with MoRE, MeV P-XD assumed a helix-turn-helix fold of three a-helices 
approximately arranged as a triangular prism (Figure 12A). One side of this prism forms the 
interface with MoRE. To map individual residues mediating P-XD interaction with L, we 
targeted amino acids located at the surface of the other two sides of the prism through charge-
reversal or charge-introducing substitutions, respectively. All of the resulting mutants were 
expressed efficiently (Figures 12B and C). Substitutions in the prism face between P-XD 
helices a1 and a2 did not affect L binding (Figure 12B), but three residues located in the face 
between a1 and a3 (V463 and S466 on a1, and H498 on a3) either abolished, or significantly 
reduced, P interaction with L (Figure 12C). Together these residues form a continuous 
microdomain covering the lower quadrant of the a1/a3 P-XD prism surface (Figure 12A). To 
test whether the absence of the C-terminal methyltransferase domain in the L1708 fragment 
impacted co-IP results, we re-examined two P mutations abolishing interaction, P (361-364)Ala 
and P-V463R, against full-length L. Neither P mutant precipitated L efficiently, validating the 
L1708-based results (figure 13).  
We next asked whether the P-V463R substitution in a1 that caused the strongest reduction 
in co-IP efficiency specifically impairs P-to-L binding or globally alters the P-XD conformation. 
To address this question, we examined its impact on the P-XD interaction with MoRE. Since N-
terminal residues of P directly bind to Ncore [56], we generated and employed P C-terminal 
fragments (PCTs) starting upstream of the tetramerization domain at P residue 231 for this 
analysis. Co-IPs of wild type PCT and the PCT-V463R mutant with standard N revealed 
efficient binding, indicating that this mutation in the a1/a3 prism face does not affect interaction 
with MoRE and thus suggesting that global P-XD folding is intact (Figure 12D). The assay was 
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validated through F497D or D493K substitutions, which are located in the hydrophobic core of 
P-XD between a2 and a3 [66] or predicted to reside on the surface of the MoRE-binding face of 
P-XD, respectively, and each indeed destroyed the interaction (Figure 12D).  
 
 
 
 
 
 
 
 
 
39 
 
Figure 12. Identification of a specific L-binding face of the triangular prism fold of P-XD 
with regulatory effect on RdRP bioactivity A) Structural representations of MeV P-XD (PDB: 
1T6O; only the P-XD component is represented), shown in side and top views. Areas between 
helices a1/a2 (red) and a1/a3 (blue) form faces of the prism without known interaction partners 
or bioactivities. Specific residues on each face are specified. Top view shows the known MoRE-
binding face of P-XD between helices a2/a3 (yellow), residues confirmed (F497) or predicted 
(D493) to respectively impair P-XD fold or MoRE binding when mutated are highlighted. Grey 
background represents space-fill surface model. B, C) P:L interaction analysis of P mutants with 
individual substitutions of residues specified in (A), forming the “red” and “blue” prism 
surfaces or implicated in MoRE binding (yellow). Detection and quantitative analysis as in 
Figure 1C (n = 4 (B); n = 3 (C)). D) PCT:N interaction after mutation of residue D493 on the 
MoRE interaction face of P-XD. Anti-N antibodies were used for IPs and anti-HA to detect PCT 
variants. E) Minireplicon analysis of RdRP activity in the presence of the specified P mutants. 
Columns represent means of experimentally observed values ± SD, symbols show individual 
biological repeats (n ³ 3). F) Observed RdRP activity in minireplicon assays in the presence of 
different P-V463R (M3) and wt P ratios as graphically depicted below the graph. Symbols show 
means of experimentally observed biological repeats ± SD (n = 3). Solid lines represent activity 
curve predictions according to a linear combination model as in Figure 2E. The dotted line (red) 
represents the best fit curve of the experimental data based on a non-linear pairwise P-XD 
competition model, goodness of fit (R2) is indicated. G) Mathematical description of the model 
represented in (E). P-XD bioactivities considered and the corresponding weight assignments are 
specified. All statistical analyses and symbols as detailed in Figure 1 (***, p ≤ 0.001).  
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Figure 13. Effect of P (361-364)Ala and P-V463R mutations on P binding to full-length 
L. Interaction analysis was carried out as specified in Figure 5C, using equally Flag epitope-
tagged L1708 and full-length L as co-IP targets. 
 
Bioactivity testing of all P-XD mutants in minireplicon assays demonstrated a direct 
correlation between the effect of substitutions in the a1/a3 P-XD prism face on L binding and 
RdRP bioactivity (Figure 12E). a1 substitutions V463R and S466R and the a3 mutation H498R 
in particular eliminated all polymerase activity, as did the F497D and D493K changes 
suppressing P-XD binding to MoRE. Competition profiles of the P-V463R mutant with wild type 
P revealed remarkable RdRP hyper-activity at higher relative amounts of the V463R mutant, 
more than double that seen in the presence of wild type P alone (Figure 12F). Also, this 
experimental data set was incompatible with a linear combination function.  
We, therefore, considered again non-linear models, based on the following assumptions: all 
four P-XDs within a P tetramer function independently of each other; bioactivity requires XD 
binding to L and MoRE; both wild type and mutant XDs are equally MoRE binding competent; 
and the V463R mutation selectively impairs XD interaction with L only. Most notably, the best 
fit (R2 = 0.80) mathematical description of the experimental data critically depends on the 
addition of a strong negative effect on bioactivity that arises from P-XD competition for L 
binding (Figure 12G). This model assumes that a single L binding-competent XD in the P 
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tetramer is necessary and sufficient for bioactivity of the RdRP complex. Corroborating RdRP 
hyperactivity seen in the earlier PDXD competition profiles, these results for the MoRE binding-
competent but L binding-defective P-V463R mutant revealed that assignment of L-binding 
competence to only one XD per P tetramer creates conditions most favorable for overall RdRP 
activity.  
1.2.7.5 Trans-complementation of P mutants with distinct L binding deficiencies in 
minireplicon and recMeV 
Having identified two discrete P microdomains that are required for interaction with L 
and highly conserved across major human pathogens in the paramyxovirus family (Figure 14), 
we explored whether these domains are functionally distinct. Co-expression of P (361-364)Ala 
and P-V463R, each by itself unable to co-IP L, restored physical interaction with L (Figure 
15A). Wild type P-like binding efficiency was observed in the presence of the highest relative 
excess of P-V463R tested. When applied to minireplicon assays, we found that successful trans-
complementation of L binding capacity extended to bioactivity of mixed P tetramers, remarkably 
resulting in RdRP activity equivalent to that observed with wild type P when cells received P 
(361-364)Ala and P-V463R-encoding plasmid DNA in approximately a 1:3-relative ratio (Figure 
15B). Trans-complementation profiles over a wide plasmid ratio range corroborated this result, 
revealing a steep, asymmetric bell curve with a wild type P-equivalent RdRP bioactivity peak at 
a relative plasmid DNA ratio of 1:3 (P (361-364)Ala:P-V463R) (Figure 15C). We conclude that 
at least two structurally and functionally distinct P microdomains are engaged in productive P-to-
L binding. Wild type P-like bioactivity in the presence of an excess of P-V463R in mixed P 
tetramers corroborates our earlier observation that designating L binding-competence to a single 
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XD per P tetramer boosts bioactivity, thus compensating for the negative effect associated with 
the presence of even one P (361-364)Ala monomer.  
 
Figure 14. Multi-sequence alignments of P proteins of selected paramyxoviruses, 
representing genera of major clinical importance. Alignment with Clustal Omega algorithm 
(MeV P (NP_056919.1); CDV P (AIN44014.1); RV P (AAB23268.1); hendra virus (HeV) P 
(APT69525.1); nipah virus (P) P (QBQ56717.1); SeV P (AAB06279.1); HPIV-1 P 
(AAL89402.1); HPIV-3 P (BAA00921.1); mumps virus (MuV) P (BAA00260.1), HPIV-2 P 
(ART66806.1), and PIV-5 (YP_138512.1). a-helical regions are highlighted above the sequences 
and heptad repeats in P-OD indicated; numbering refers to MeV. P residues 361-364 are 
highlighted in green, color-coding of individual residues in P-XD according to the scheme used 
in Figure 11A. 
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Figure 15. L-binding null-mutants in P OD C-terminal microdomain and P-XD 
efficiently trans-complement A) Graphic depiction of P (361-364)Ala / P-V463R trans-
complementation ratios tested and P:L interaction analysis of the different trans-
complementation pairs. A HIS-tagged version of the P-V463D mutant was used to enable 
differential immunoprecipitation, detection and quantitative analysis otherwise as in Figure 5C 
(n ³ 3). B) Minireplicon assay of candidate trans-complementation P mutants alone and co-
expressed at 1:3 relative ratio (n ³ 3). C) Trans-complementation RdRP activity profile of the 
pair shown in (A) and (B), analyzed in minireplicon assays over the specified relative ratio 
range. Error bars show means of biological repeats ± SD (n = 3). All statistical analyses and 
symbols as detailed in Figure 5. 
 
Minireplicon assays are highly informative for functional dissection of RdRP activities, 
but the physiological relevance of the results can be compromised by the shortcoming that only a 
subset of the multiple RdRP activities required for successful virus replication is examined [71]. 
To test whether trans-complementation restores the complete functional range of MeV RdRPs, 
we engineered a recMeV genome in which the wild type P gene was replaced with a tandem 
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arrangement of genes encoding P-V463R and P (361-364)Ala, respectively (Figure 16A). P-
V463R was intentionally placed upstream of P (361-364)Ala to capitalize on the Mononegavirales 
transcription gradient [113] and ensure that L binding-deficient P-V463R would be present in 
relative abundance over P (361-364)Ala in infected cells. The corresponding recMeV P-V463R-P 
(361-364)Ala virus was recovered successfully, replicated as efficiently as the genetic parent virus 
(Figure 16B) and displayed equivalent cytopathic effect (CPE) size (Figure 15C) and CPE 
kinetics (Figure 16D) in cell culture. Sanger sequencing of both P genes after five consecutive 
passages of four independently recovered recombinants confirmed the integrity and genetic 
stability of both P mutations in replicating virus (Figure 16E). Like all paramyxovirus RdRPs, 
MeV polymerase is error-prone, and mutations advantageous for viral fitness become genetically 
fixed rapidly [114]. The clean chromatograms at both mutation sites in all recMeV examined 
indicate a remarkable lack of selective pressure to acquire revertant or compensatory mutations. 
This observation was consistent with the parent recMeV-like growth profiles of the double 
mutant virus and underscores that all P bioactivities required for unimpaired virus replication are 
restored through trans-complementation.  
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Figure 16. A) Graphic genome representations of standard MeV (strain IC-B) and trans-
complementation candidate. The relative positions of the P-V463R (red) and P (361-364)Ala 
(blue) genes are highlighted. B) Viral growth curves after recovery of parent recMeV IC-B and 
trans-complemented recMeV IC-B P-V463R-P (361-364)Ala. Symbols represent mean titers of 
biological repeats ± SD (n = 3). Statistical analysis through two-way ANOVA with Sidak’s post-
hoc comparison tests. C) Microphotograph time-courses of uninfected Vero-hSLAM cells (mock) 
or cells infected with recMeV IC-B or recMeV IC-B P-V463R-P (361-364)Ala, taken in 4-hour 
intervals from 24-36 hours after infection. Each series shows a specific area, monitored over 
time. D) Quantitation of CPE kinetics after infection of cells with standard and trans-
complemented recMeV. Syncytia sizes in 10 distinct areas/virus were quantitated automatically 
using a high-content imager, and are each expressed as fold-change increase in syncytia size (in 
µm2 area covered) relative to syncytia size at the same plate coordinates at 24 hours pI. 
Columns represent means of experimentally observed values ± SD, symbols show individual 
repeats (n = 10); NS not significant. E) Chromatograms of P sequences at mutated areas of 
recovered recMeV IC-B and recMeV IC-B P-V463R-P (361-364)Ala  after five serial passages on 
Vero-hSLAM cells. Encoded amino acids are specified above the chromatograms. 
 
1.2.7.6 OD proximal and connector region residues reside in the same functional group 
To scan the approximately 80-residue connector region between the P OD C-terminus and 
P-XD for amino acids potentially contributing to L binding, we explored heterotypic interactions 
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between MeV and very closely related CDV P and L. Both viruses share considerable protein 
sequence homology and identity, and heterotypic co-IPs confirmed that MeV P associates with 
MeV or CDV L with equal efficiency (Figure 17). Heterotypic interaction suggests that any 
residue in the connector region contributing to P-to-L binding should be conserved between both 
viruses. We identified nine distinct microdomains of three to four consecutive identical amino 
acids in sequence alignments of the MeV and CDV P connector regions (Figure 18A) and 
subjected each individually to alanine scanning mutagenesis. 
 
Figure 17. Homo- and hetero-typic interaction of MeV L with P derived from MeV or 
CDV, respectively. Interaction analysis, immuno-detection and signal quantitation in Figure 5C. 
Columns show means ± SD, symbols represent individual biological repeats (n = 3). Statistical 
analysis through unpaired T-test (NS, not significant). 
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Figure 18. Residues in the connector region between P position 377 and 458 trans-
complement P-XD mutations but are functionally linked to the OD C-terminal microdomain A) 
Alignment of MeV and CDV P sequences between residues 351 and 490. Conserved patches (³3 
identical residues) are underlined and numbered consecutively. B) P:L interaction analysis of P 
mutants with alanine substitutions of residues in conserved patches identified in (A; red 
numbers). Detection and quantitative analysis as in Figure 5C (n = 3). C) Minireplicon 
competition experiment between P (404-407)Ala and wt P, set-up as in Figure 2D and E. Symbols 
show means of relative RdRP activity ± SD, three biological repeats. Blue and black lines show 
competition profiles respectively between P-V463R (Figure 12G) and P (361-364)Ala (Figure 
7E). Statistical analysis with two-way ANOVA and Sidak’s post-hoc multiple comparison test. D) 
Trans-complementation minireplicon assays of P (404-407)Ala with P (361-364)Ala and P-V463R, 
respectively, relative ratios of P-encoding plasmid DNA transfected as specified. Columns 
represent mean relative RdRP activities ± SD, symbols show biological repeats (n = 3). 
Statistical analyses in (B) and (D) and symbols as in Figure 5.  
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Co-IPs with the resulting MeV P mutants highlighted a stretch of four consecutive 
conserved patches in the connector domain, spanning P residue 396 to 410, that significantly 
impaired P-to-L interaction when mutated (Figure 18B). A local co-precipitation minimum was 
reached by the P (404-407)Ala mutant. However, all mutants tested with alanine substitutions in 
the connector domain, including those capable of physical interaction with L, significantly 
reduced P bioactivity in minireplicon assays (Supporting Figure S8). When increasing amounts 
of P (404-407)Ala were co-transfected with wild type P in minireplicon competition assays, 
bioactivity profiles markedly differed from those of the P-XD mutants but closely resembled the 
dominant-negative P (361-364)Ala (Figure 6C). Trans-complementation of P (404-407)Ala was 
likewise successful with P-V463R but not with P (361-364)Ala (Figure 12D), placing the P OD 
C-terminal residues and connector region in the same complementation group, each functionally 
distinct from the L binding face of P-XD.  
Co-IPs with the resulting MeV P mutants highlighted a stretch of four consecutive 
conserved patches in the connector domain, spanning P residue 396 to 410, that significantly 
impaired P-to-L interaction when mutated (Figure 18B). A local co-precipitation minimum was 
reached by the P (404-407)Ala mutant. However, all mutants tested with alanine substitutions in 
the connector domain, including those capable of physical interaction with L, significantly 
reduced P bioactivity in minireplicon assays (Figure 19). When increasing amounts of P (404-
407)Ala were co-transfected with wild type P in minireplicon competition assays, bioactivity 
profiles markedly differed from those of the P-XD mutants but closely resembled the dominant-
negative P (361-364)Ala (Figure 18C). Trans-complementation of P (404-407)Ala was likewise 
successful with P-V463R but not with P (361-364)Ala (Figure 18D), placing the P OD C-terminal 
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residues and connector region in the same complementation group, each functionally distinct 
from the L binding face of P-XD.  
 
Figure 19. Minireplicon analysis of relative bioactivity of P mutants with alanine 
substitutions in conserved patches in the connector domain (specified in Figure 13A; red 
numbers). Columns show means ± SD, symbols represent individual biological repeats (n = 3). 
Statistical analysis through one-way ANOVA and Tukey’s multiple comparison test (NS, not 
significant; ***, p ≤ 0.001; ****, p ≤ 0.0001). 
 
1.2.7.7 P-XD is a central regulator of the dynamic interplay between polymerase and 
encapsidated template 
To query whether the same P-XD monomer in a P tetramer must be both L and MoRE 
binding-competent to support RdRP activity, we examined trans-complementation of the P-
D493K mutation abrogating P-XD-to-MoRE binding with P-V463R blocking P-XD-to-L 
interaction at different relative ratios. Efficient trans-complementation occurred between MoRE-
binding impaired (L+ MoRE–) and L-binding defective (L– MoRE+) P-XDs (Figure 20A). Albeit 
trans-complementation efficiency was reduced at each of the ratio extremes (1:10 and 10:1, 
respectively), presumably reflecting an accumulation of a large proportion of bio-inactive 
homotypic mutant tetramers under these conditions, appreciable RdRP activity remained (Figure 
20B). We then attempted trans-complementation between P-D493K and P (361-364)Ala. Since 
our mathematical modeling has demonstrated that at most one P (361-364)Ala monomer can be 
present in a bioactive P tetramer, this mutant enabled us to probe the stoichiometric requirements 
of the different P-XD functionalities. In contrast to our successful earlier trans-complementation 
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of (L– MoRE+) P-XDs with P (361-364)Ala, the combination of (L+ MoRE–) P-XDs with P (361-
364)Ala did not restore RdRP activity. These results indicated that the presence of one MoRE 
binding-competent or one L binding-competent XD per P tetramer is sufficient for RdRP 
activity, but these competencies must not reside on the same P-XD if the other three P-XDs are 
unable to interact with MoRE (Figure 20B).  
Three-way trans-complementation studies, in which we paired each of the three 
functional groups tested in all possible combinations reinforced this conclusion, since P-V463R 
efficiently trans-complemented with a P-D493K - (361-364)Ala double mutant, while the 
combination of P-V463R-D493K with P (361-364)Ala was bio-inactive (Figure 20C and D). The 
presence of only one each L and MoRE binding-competent XD in P tetramers is therefore 
necessary and sufficient to achieve approximately wild type P-like bioactivity, but both binding 
partners cannot be simultaneously engaged by the same P-XD monomer. Interaction of a P-XD 
with L takes priority over MoRE binding when the number of fully functional XDs present in 
mixed P tetramers is restricted. These data reveal P-XD as a regulatory element of the highly 
dynamic and multi-faceted protein-protein interplay between RdRP and the RNP template, 
placing it at the center of a mechanistic model of polymerase advancement. 
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Figure 20. 2-way and 3-way trans-complementations to probe stoichiometric 
requirements of the different P-XD functionalities in bioactive RdRP complexes A, C) Trans-
complementation minireplicon assays of P single and double mutants as specified. Relative 
ratios of P-encoding plasmid DNA transfected are indicated. Columns represent mean relative 
RdRP activities, symbols show individual biological repeats ± SD (n ³ 3). Statistical analyses 
through one-way ANOVA and Tukey’s multiple comparison test, symbols as detailed in Figure 1. 
B, D) Schematic overview of the predominant P tetramer populations of selected trans-
complementation pairs from (A) and (C) as specified. P-encoding plasmid DNA ratios 
transfected are indicated and mean relative RdRP activities are color-coded (green, wild type P-
like activity; yellow, hyper-active; magenta, inactive). Boxes represent dominant XDs 
composition of trans-complemented mixed P tetramers. Open boxes indicate L (L) or MoRE (M) 
binding-competence, crossed boxes denote the presence of loss-of-function substitutions for the 
respective binding activity. E) Mechanistic summary model of P interaction with L and P-XD-
mediated regulation of RdRP negotiation of the N-encapsidated template. Individual XDs of the 
P tetramer are differentiated by color, Ncore and MoREs are shown in gold. Roman numerals in 
close-up inserts depict specific interactions identified through trans-complementations and are 
discussed in the text. A model for RdRP activity boosting by the signature trans-complementation 
pair P-V463R / P (361-364)Ala is shown on the right. 
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1.2.8 Chapter 1 Discussion 
This study demonstrates that distinct microdomains in MeV P are involved in efficient P 
hetero-oligomerization with L. We favor the view that these microdomains engage L through 
direct protein-protein contacts, although more indirect associations involving, for instance, host-
derived adapter proteins cannot be excluded. Here, the term P:L interface will be used to refer to 
both direct and multi-component interactions between the P and L proteins. Based on a 
combination of biochemical and functional assays, we have pioneered a trans-complementation 
system to probe the stoichiometric requirements for productive P:L interactions. While trans-
complementations were carried out in minireplicon assays, a recombinant MeV carrying a P 
trans-complementation pair in two tandem open reading frames could be recovered readily, 
efficiently proliferated with a standard MeV-like growth profile and was genetically stable over 
multiple passages. The absence of compensatory or reversion mutations, in particular, serves as a 
compelling indicator that the mutant recMeV does not experience strong selective pressure. 
These results confirm that trans-complementation restored all RdRP activities required for 
successful paramyxovirus replication. Thus, assured of the physiological relevance of the 
strategy, the assay has advanced our mechanistic understanding of how paramyxovirus RdRp 
negotiates the encapsidated template in four areas:  
  i) The P:L interface is bipartite. P monomers were unable to interact with L, but 
replacement of P-OD with yeast GCN4 was tolerated, demonstrating that P tetramerization is 
essential for L binding. In contrast to previous suggestions [86], however, residues located in the 
P OD core section are not part of the physical interface. Rather, a 17-residue stretch at the C-
terminal end of P OD mediates L binding after extension of the helical coiled-coil up to residue 
377. This conclusion is supported by the natural continuation of the heptad repeat patterns of P 
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OD through to position 377, complete abrogation of the ability of L to co-IP with P after 
insertion of alanine substitutions in this microdomain, and the dominant-negative competition 
profile of P (361-364)Ala with wild-type P. It furthermore is consistent with a very recent study 
demonstrating that the coiled-coil OD of MeV P is required for viral gene expression [93]. 
Mathematical description of the experimentally determined data revealed that in the presence of 
both P (361-364)Ala and wild type P, only mixed P tetramers harboring precisely one copy of this 
mutant are bioactive. We have thus shown that three wild type P monomers are able to 
structurally control one mutant and form proper tertiary assemblies, but two or more P (361-
364)Ala subunits in a P tetramer cannot be contained.  
Downstream of the P OD proximal section, we identified a conserved second microdomain 
centered around P residues 404-410 that was a major determinant for the efficiency of P-to-L 
binding. Changes in this connector region likewise had a dominant-negative effect on P 
bioactivity, suggesting that the section between P OD and P-XD very likely does not exist 
monomeric in P complexes, but engages in a tertiary assembly. Trans-complementation revealed 
that the P-OD proximal and connector sections reside in the same functional groups, raising the 
possibility of an extended interface with L or, if only one of these regions engages in physical 
contact with L, interference of mutations in the other microdomain with proper assembly of the 
actual contact zone.  
Remarkably, we identified specific residues located on two different a-helices of P-XD that 
are essential for P-to-L binding. These residues map to a microdomain on a previously 
unappreciated face of the P-XD triangular prism that is distinct from the side binding MoRE. 
Importantly, this microdomain resides in a separate functional group from the P OD proximal 
and connector regions, and mutations destroying this newly discovered L-binding face of P-XD 
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were recessive in competition studies with wild type P. These results indicate that the P-XD 
interaction with L is mediated by a single XD subunit of the P tetramer, and that at least two 
distinct binding sites for different P microdomains exist on L, the P oligomerization domain-
proximal tetrameric regions (tetrameric feet) and the P-XD (monomeric head) (Figure 20E). 
Neither site was able to form biochemically appreciable complexes with L in isolation, indicating 
moderate binding affinities of both interfaces. The formation of stable P-L hetero-oligomers 
appears to require the avidity gain arising from at least two independent contact sites.  
ii) Only one each of the four XDs per P tetramer must be L or MoRE binding-competent 
(Figure 20B-1, 2 and 20D-1). By introducing point mutations in P-XD to the trans-
complementation assay that selectively disrupt MoRE or L binding, we demonstrated that a 
single MoRE binding-competent P-XD is sufficient for wild type P-like RdRP bioactivity 
(Figure 20B-2). This finding is paradigm-shifting since prevailing models assign cartwheeling 
function to the four XDs of a P tetramer [115, 116], in which the polymerase supposedly 
advances along the RNP template through iterative formation and release of P-XD contacts with 
MoRE, ensuring that at all times at least one intact P-XD-MoRE interface is present. Our results 
demonstrate that no stringent requirement exists, and no P-XD-mediated cartwheeling needs to 
occur. This conclusion is also consistent with our earlier observation that RNPs formed by N 
mutants with tail deletions encompassing the C-terminal 86 amino acids that include MoRE are 
partially bioactive [71]. 
iii) P-XD interaction with L and MoRE is mutually exclusive, and L-binding of a given P-
XD supersedes MoRE-binding (Figure 20D-2, 20B-3 and 4). These conclusions are based on 
the central premise revealed by the mathematical regression analysis of the P (361-364)Ala 
competition profile with wild type P, that at most one P (361-364)Ala monomer can be present in 
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bioactive mixed P tetramers. Employing the P (361-364)Ala mutant as a tool to control the 
stoichiometry of trans-complemented P tetramers, we noted that although only one each of the 
four P-XDs must be L or MoRE binding-competent, combining these competencies on only one 
P-XD per tetramer completely abrogates polymerase activity (Figure 20D-2). Presumably, steric 
hindrance prevents that the same P-XD simultaneously engages both MoRE and L. Importantly, 
the presence of only one (L+ MoRE+) P-XD and three (L– MoRE+) P-XDs in a mixed P tetramer 
was sufficient to restore wild-type P like polymerase activity (Figure 20B-3), but the inverse 
constellation (one (L+ MoRE+) P-XD and three (L+ MoRE–) P-XDs) was entirely bio-inactive 
(Figure 20B-4). This complementation phenotype revealed the dominance of the P-XD 
interaction with L over MoRE but raised the question of why in the constellation depicted in 
Figure 20B-4 75% of the P-L hetero-oligomers (those in which one of the (L+ MoRE–) P-XDs 
happens to contact L) did not remain bioactive.  
iv) During RNA synthesis, P-XD iteratively separates from and reengages with L (Figure 
20B-1 and 4). In all trans-complementation constellations that assigned L-binding competence to 
only one P-XD, we consistently noted a boost in RdRP bioactivity compared to wild type P 
tetramers. This unexpected phenotype can be best appreciated in the Figure 19B-1 setting, but is 
equally present in the Figure 20B-3 and Figure 20D-1 constellations, since the addition of only 
one P-(361-364)Ala monomer to otherwise wild type P tetramers reduced bioactivity by 
approximately 40% according to our regression model. Consequently, the wild type P-like 100% 
bioactivity seen for the Figure 20B-3 and Figure 19D-1 constellations reflects a near-perfect 
additive effect of the activity booster resulting from P-XD assignment and penalty associated 
with the presence of a P-(361-364)Ala monomer. Our competition studies of the P-V463R mutant 
with wild type P returned even higher peak RdRP values reaching 250% of reference bioactivity.  
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What could be the mechanistic basis for a boost in RdRP activity when only one P-XD subunit 
is able to interact with L? A previous study considered that negotiation of the encapsidated 
template by paramyxovirus polymerases might depend on continuous structural rearrangements 
within the RdRP complex, possibly including the repetitive dissolution and reassembly of P:L 
interaction [117]. Based on our identification of a bipartite P:L interface and the trans-
complementation data, we propose that the newly discovered P-XD:L interface periodically 
resolves and reforms. In wild type P tetramers, all four P-XDs are L binding-competent. Iterative 
separation of P-XD from L creates an opportunity for competition between the individual P-XDs 
to reengage with L and/or need for rearrangement within the P-L hetero-oligomer every time a 
physically different P-XD than before is successful. Delegating L binding to a designated P-XD 
monomer as in our mixed P tetramers eliminates internal competition and associated 
rearrangements of the complex, unleashing maximal polymerase processivity. This conclusion is 
consistent with the mathematical description of our experimental data and provides ready 
explanations for why a bipartite P:L interface may have evolved – two distinct contact zones allow 
temporary separation of only the P-XD:L interface without presumably catastrophic full separation 
of P from L – and why the trans-complementation pair depicted in Figure 20B-4 is bio-inactive. If 
P-XD indeed transiently separates from and rebinds to L as the polymerase advances along the 
template, the single (L+ MoRE+) P-XD monomer present in every RdRP complex that can 
potentially initiate RNA synthesis in this constellation will eventually engage L. Because no other 
MoRE binding-competent P-XDs are present in that P tetramer, this event appears to create a dead-
end situation, presumably resembling that experienced by the trans-complementation pair 
represented by Figure 20D-2.  
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We propose a 4-step model to describe the dynamic interplay between P, L, and the RNP 
(Figure 20E). The tetrameric base of P remains latched to L at all times, while the P-XD head 
reiteratively taps L. In the case of wild type P, one P-XD forms a temporary complex with L 
while another P-XD binds MoRE (stage I). MoRE engagement is thought to induce 
reorganization of N-tail [118], moving it closer to the core of the RNP helix (stage II). Possibly 
this change in microenvironment of the binding partners may destabilize the interfaces, resulting 
in temporary separation of both P-XD:MoRE and P-XD:L, which enables the advancement of 
the polymerase to the next N protomer (stage III). One of the four P-XDs then rebinds to L and 
another engages the MoRE of the new N protomer (stage IV), followed by a repeat of the cycle. 
Assignment of L-binding competence to a specific P-XD does not fundamentally change the 
process, however, P-XD competition for the L binding site as well as potential rearrangements 
within the complex when a separate P-XD moiety is present are eliminated because at every 
cycle the same P-XD monomer rebinds to L (stage III’ to IV’). The remaining two P-XDs, not 
fully depicted in Figure 20E, may or may not engage other MoREs in the vicinity. However, 
these interactions are not essential for polymerase activity, if they occur. This mechanistic model 
assigns a fundamental role in regulating polymerase activity to the paramyxovirus P protein and 
identifies a novel principle, reiterative separation and restoration of P-XD interaction with L, that 
kinetically regulates RdRP negotiation of the encapsidated RNA template. 
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1.3 Chapter 2: Identification of a novel RABV entry inhibitor 
1.3.1 RABV Disease and Current Treatment 
Derived from the Latin word for madness, rabies is an ancient zoonotic viral disease that 
continues to be a global public health concern causing approximately 60,000 deaths annually. 
Considered the most lethal vaccine-preventable viral disease, rabies has a world-wide 
distribution of animal reservoirs and cases have been reported in over 150 countries and 
territories with 95% of cases occurring in developing countries within Asia and Africa [119]. 
The etiological agents of rabies disease, lyssaviruses, are characterized as negative-sense non-
segmented RNA viruses that are grouped in the Rhabdoviridae family. The majority of zoonotic 
transmission events of RABV are from animal bites that expose the open wound to infectious 
saliva. After an asymptomatic incubation period that can last from a few days to up to one year, 
RABV enters the central nervous system via retrograde neuronal transport. Subsequently, the 
virus causes severe inflammation of the brain and spinal cord [120]. Most cases of rabies disease 
result in the furious form of rabies that causes hyperactivity, hydrophobia, and excitability within 
patients and eventually leads to death from cardio-respiratory failure. The less-common form of 
rabies disease, paralytic rabies, presents as a slow paralysis stemming from the initial site of 
infection that gradually takes over the body and is followed by a coma preceding death [121]. 
Diagnosis of rabies is only possible in late stages of infection due to immune evasion strategies 
of RABV and the treatment window closes once clinical signs develop [7]. Post-exposure 
prophylaxis treatment (PEP) of rabies disease for naïve individuals consists of passive 
immunization with human-derived anti-RABV immunoglobin (hRIG) combined with RABV 
vaccine on the day of exposure, followed by three additional doses of vaccine given on days 0, 3, 
7, and 28 (Figure 21). For previously vaccinated individuals, the vaccine is administered on days 
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0 and 3 per WHO guidelines [7, 119, 122]. Although there are early and effective treatment 
options available both in the United States and abroad, the cost of PEP has increased by almost 
400% in the past decade. Currently, in the United States, the cost of PEP can exceed 
$3,000/dose. In Africa and Asia, this cost equates to nearly 40-times an average daily income 
[119]. Prohibitive cost and limited supply of hRIG has led some countries to try alternative and 
more economical PEP treatments, such as equine RIG (eRIG). Treatment with eRIG, though 
effective, has resulted in severe adverse side effects including anaphylaxis, serum sickness, and 
other allergic reactions [123-125]. The exorbitant price and ineffectiveness of the current PEP 
treatment against emerging zoonotic phylogroup II lyssaviruses such as Mokola virus (MOKV), 
and Lagos bat virus have underscored an unmet clinical need for discovery of efficacious 
antiviral treatment against RABV [121, 126].   
 
Figure 21. Schematic diagram representing the current post-exposure prophylaxis 
treatment (PEP) schedule as recommended by the WHO for naïve individuals (from Du Pont et. 
al., 2018) [126]  
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1.3.2 RABV Genome and Virion Organization and Replication  
 
 
Figure 22. RABV Genome, Virion and Lifecycle A) Schematic diagram of RABV genome 
organization. B) Diagram of bullet-shaped RABV virion. Host-derived envelope (black), L 
(lavender), P (yellow), N/RNP (orange), G (dark green), and M (light green) are denoted. C) 
Replication cycle of RABV 
 
RABV is a negative-sense nonsegmented RNA virus of the lyssavirus genus within the 
viral family Rhabdoviridae. The viral genome, which consists of aproximately 12,000 
nucleotides, encodes five structural proteins, N, P, M, G, and L (Figure 22A) [128]. The host-
derived viral envelope has a characteristic bullet-shape due to a complex of two nested left 
handed helices comprising of a spiraling inner layer of N encapsidated viral genome coated by 
an outer layer of M protein (Figure 22B) [129]. Host receptor binding and endocytotic viral 
entry is mediated by G, a trimeric type 1 membrane protein on the surface of the virion. 
Interaction of G with host cellular receptors (NCAM, p75TR, and aChR) triggers endocytosis of 
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the virion in a clathrin-dependent manner using the endosomal transport pathway [130-133]. 
Release of the RNP occurs after low pH-induced fusion between G and the endosomal 
membrane (Figure 22C)[134, 135]. L and P constitute the functional RdRP heterocomplex and 
are pre-loaded onto the genome to form the RNP. Viral replication and transcription occur within 
viral factories within the cytoplasm called Negri bodies [136, 137].  Transcription begins at the 
3¢ leader end of the viral genome. Viral monocistronic mRNAs are transcribed using 
genomically encoded start and stop signals, beginning with the N ORF. All mRNAs are capped 
and polyadenylated by L. The 3¢-poly(A) tail consists of approximately 100-250 nucleotides. 
VSV L has been shown to have a unique capping mechanism that uses GDP as the methylation 
moiety for the cap structure via a specialized PRNTase domain. It is also assumed RABV caps 
mRNA in a similar fashion due to conservation of the PRNTase domain within the family [4]. A 
transcriptional gradient occurs during viral mRNA synthesis that results in a gradual decrease of 
transcripts starting from the 3¢ leader to the 5¢ trailer due to attenuation of reinitiation of the 
polymerase complex and variable intergenic seqeunce (IGS) lengths [138]. Replication of the 
viral genome occurs when RABV ignores transcription cues to produce antigenome, which in 
turn is used as the template to replicate genomic RNA. Both genome and antigenome are 
concomitantly encapsidated by N during replication. This process is faciliatated by N0P 
complexes, whose accumulation has been implicated in the switch from the transcriptase to 
replicase mode for the polymerase [139, 140]. The RABV M also modulates polymerase activity 
by inhibiting transcription and stimulating replication [141, 142]. M coats and condenses the 
RNP and budding is facilitated by recruitment of ESCRT machinery and interaction with 
cytoplasmic tails of G [51]. Interestingly, it was found that budding still occurs in the absence of 
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G, however egress is a much slower and less efficient process that leads to more cell-associated 
virions, which has been used to facilitate pseudotyping [143]. 
1.3.3 Current RABV Treatment 
The onset of clinical symptoms of rabies disease is universally fatal, however, there exist 
rare documented cases of survival after aggressive treatment was administered. All patients, 
except one, received doses of PEP combined with vaccine and all patients developed life-long 
neurological sequelae [122]. Also, because of the rarity of survival from symptomatic rabies, 
there exists debate whether the surviving patients actually were infected with RABV due to the 
absence of virus or viral antigens. The single survivor without PEP had undergone the 
Milwaukee Protocol (MP). The MP is a combinatorial therapy including a ketamine-induced 
coma with regular administration of ribavirin, midazolam, heparin, amantadine, and high doses 
of benzodiazepines and barbiturates [144]. The induction of coma is predicted to reduce neuronal 
cell damage and slow disease progression by reducing over-stimulation of brain cells. 
Presumably this also enables time for the adaptive immune response to develop protective 
antibodies. The singular success of the MP, and the 31 documented failures thereafter has 
prompted speculation that the survival of the MP patient was due to infection with an atypical 
RABV strain or low virulence within the bat that bit her [144-149]. The aggressive treatment 
options for pre- or post- symptomatic rabies include ribavirin, interferon-a (IFN-a), and 
ketamine/amantadine. Ribavirin is a broad-spectrum antiviral analogue of guanosine.  Ribavirin 
has shown in vitro efficacy against several encephalitis inducing viruses, including Japanese 
encephalitis virus, West Nile virus, Argentinian hemorrhagic fever, hantavirus pulmonary 
syndrome, influenza, RSV, human immunodeficiency virus, MeV and CDV [27, 150-155]. 
Ribavirin has multiple mechanisms of action that directly affect RNA and DNA synthesis in 
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addition to inhibition of the de novo purine synthesis pathway [156-158]. So far, no clinical 
effect has been observed after treatment of rabies with ribavirin, and in vivo studies have 
demonstrated that it exhibits marginal penetration across the blood-brain barrier (BBB), though 
low levels were detected in cerebrospinal fluid after oral administration to HIV patients after 
several weeks [159-161].  
IFN-a is a type I interferon has been administered to induce triggering of the innate 
immune response pathways. However, the lyssavirus P gene produces multiple truncated 
isotypes designed to antagonize the interferon-driven innate immune response. All P isotypes act 
directly to prevent STAT1 migration to the nucleus. P1 and P2 directly engage STAT1 and 
sequester it to the cytoplasm by encoding a nuclear export signal, P3 competitively binds to the 
STAT1 DNA binding site, as well as binds microtubules to block STAT1 shuttling to the nucleus 
[162]. The antagonistic properties of RABV P against STAT1 functionality make IFN-a a poor 
anti-viral treatment. The dissociative anesthetic, ketamine, rapidly penetrates the BBB and at 
prohibitively high concentrations has been shown to inhibit genomic replication of RABV in rat 
cortical neurons [163]. Even though ketamine was used in the MP, it was more likely included 
for its sedative properties than for potential therapeutic uses.  
1.3.4 RABV Drug Discovery 
As denoted in Tables 1 and 2, there have been multiple small-scale attempts at antiviral 
drug discovery against RABV, however, identification of druggable targets remains a great 
hindrance for advancement of small molecule hit candidates [127]. Druggable targets are 
identified by their affinity to bind to a commercially viable compound (i.e. one that is 
bioavailable and adheres to Lipinski’s rule of five) that affects physiological function and 
provides therapeutic benefit [164].    
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One approach of antiviral drug discovery often implemented is the identification and 
indirect targeting of essential host proteins exploited by RABV for replication and pathogenesis. 
By indirectly targeting the viral lifecycle, there are several advantages over direct-acting 
antivirals (DAA):  
i) There is a high barrier for resistance against host-targeting antivirals (HTA) due to host genetic 
stability provided by the proofreading capabilities of host polymerases in contrast to the low 
fidelity of viral polymerases.  
ii) There are numerous host proteins that RABV exploits compared to the limited number of 
druggable viral proteins.  
iii) There are a plethora of FDA-approved drugs targeting pro-viral host factors that can be 
repurposed to fast-track antiviral development.  
iv) Broadened antiviral indication can be achieved by targeting commonly used pathways by 
members of the viral family, e.g. emerging viruses such as the phylogroup II lyssaviruses.   
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Table 1. Host-directed RABV inhibitors 
Compound Target EC50 (uM) CC50 
(uM) 
SI 
(CC50/EC50) 
Ref. 
Catechin 
 
Host 
Cell 
GAGs 
36.50 ± 8.40 
 
124.33 ± 33.53 
 
3 [164, 
165] 
Quercetin 
 
Host 
Cell 
GAGs 
191.68 ± 24.25 
 
670.02 ± 180.18 
 
3 [164, 
165] 
3,4,5-Trimethoxybenzoic 
acid 
 
Host 
Cell 
GAGs 
2142.74 ± 266.3 
 
>5042.41 
 
2 [164, 
165] 
Trimethoxyacetophenone Host 
Cell 
GAGs 
1023.98 ± 64.62 
 
3738.98 ± 1099.17 
 
3 [164, 
165] 
3,4,5-Trimethoxybenzoic 
acid ethyl ester 
 
Host 
Cell 
GAGs 
822.23 ± 134.38 
 
3204.20 ± 397.87 
 
3 [164, 
165] 
Butyl gallate 
 
Host 
Cell 
GAGs 
109.79 
 
113.23 ± 52.35 
 
1 [164, 
165] 
PAV-866 
 
ABCE1 ∼0.15–0.30 
 
∼2.5–10 
 
~100 [166] 
Sorafenib Tyrosine 
Kinases 
1.463 >160 109 [167] 
2-piperidin-3-yl-
benzothiazole analog 
 
Nedd4 0.345 
 
>1 >3 [168] 
1-acetyl-3-(2,2,2-
trifluoroethyl)-urea analog 
 
Nedd4 0.210 >1 >8 [168] 
*Table from Du Pont et al., 2019 [126] 
Despite the promising advantages of HTAs, there are disadvantages such as cytotoxicity, 
irreproducibility in vivo, or prohibitively high 50% effective dose concentrations (EC50) that 
impede serious development initiatives, as shown in Table 1 [170]. This is particularly evident in 
the current trend of repurposing cancer drugs for antiviral therapy [171]. RABV, like many other 
viruses, depends on the extracellular signal-regulated kinase (ERK) pathway for efficient viral 
pathogenesis. Sorefenib, a multikinase inhibitor of the ERK pathway approved for treatment of 
hepatocellular carcinomas has shown some efficacy against various viruses including 
adenovirus, MuV, chikungunya virus, dengue virus, West Nile virus, Yellow fever virus, and 
enteroviruses. Against RABV, this drug demonstrated only 77% viral inhibition in vitro, and 
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exhibited antagonistic properties when combined with ribavirin and IFN-b [172]. Not uncommon 
to cancer targeting drugs, Sorefenib has unfavorable adverse side-effects making it a poor 
candidate to advance for antiviral development [173-177]. An innovative drug screen specifically 
targeting nucleocapsid assembly identified a hit targeting the ABCE1 transporter proteins. The 
50% cytotoxic concentration (CC50) of this compound was exceptionally low 2.2-10 µM, thus 
closing the door on its potential. Minocycline has also been investigated for potential therapeutic 
use against RABV due to its ability to cross the BBB, ability to suppress HIV replication, and its 
demonstrated neuroprotective effects [178, 179]. When tested against RABV in neonatal mice, a 
disturbing turn of events revealed exacerbation of the disease by inducing an earlier onset of 
neurological symptoms [180] . And lastly, another screen of  phenolic compounds as potential 
RABV drug candidates due to previous efficacy demonstrated against other viruses [165], 
showed demonstrated >50 µM EC50 virucidal activity against RABV, which is prohibitively 
high, thus limiting foreseeable advancement of these compounds for drug development.  
      The cytotoxicity and lack of successful in vivo studies with drug candidates prompted the 
discovery of DAA, Table 2, as a promising alternative strategy for therapeutic intervention. 
RABV proteins are a rich source of druggable targets that contain multi-functional domains, lack 
cellular orthologs, and engage in dynamic PPI. The highly conserved nature of RABV N, and its 
critical function for genome encapsidation and RdRP recruitment makes it an enticing druggable 
target. Several studies have shown that RNA interference (RNAi) technology targeting N can 
inhibit viral replication in vitro [181-185]. When tested in vivo however, there was only a 60% 
survival rate against RABV [181]. Similarly, small hairpin RNAs targeting N delivered by 
adeno-derived viral vectors were also shown to inhibit RABV and marginally increase the 
survival rate of mice [182]. Despite the promising avenue of RNAi therapy, the mode of efficient 
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delivery remains a barrier for effective antiviral treatment and was considered the reason for 
failure with these studies. The heterocomplex formation between RNP and P has also been 
investigated as a potential antiviral target. In an attempt to generate a broad-spectrum lyssavirus 
inhibitor, a Y2H screening assay was employed against both RABV P and MOKV P. The study 
identified several peptides with antiviral effect against RABV infection due to disruption of the 
RNP-P interaction when tested in peptide-transfected cells [186]. Similarly, peptides were shown 
to inhibit infection of neuronal cells by specifically targeting the amino terminal 42 and 60 
residues of P [187]. Neither of these studies tested the peptides for in vivo efficacy and despite 
antiviral effect and high specificity, efficient drug delivery of therapeutic peptides remains a 
difficult and expensive obstacle to overcome [170]. The strong homology between lyssaviruses 
gleaned from recent structural information potentiates structure-guided design of broad-spectrum 
small-molecule inhibitors with cell permeability. 
 
Figure 23. Rabies virus glycoprotein A) Linear schematic of RABV G organization and 
amino acid position of the extracellular domain, the transmembrane domain, and the 
cytoplasmic domain. B) Homology model of RABV G trimer based on VSV G (PDB: 2J6J) and 
division of each functional domain: trimerization domain (orange), and fusion domain (yellow). 
[187-190] 
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The primary PEP approach to combating RABV infection remains antibody therapy 
specifically targeting G (Figure 23 A,B). Despite continued and reasonably successful efforts to 
develop cross-strain antibodies, antigenic drift, cost, and cold-chain requirements prevent them 
from being a viable solution for individuals in developing nations that require PEP the most. Not 
to mention the lack of efficacy of PEP after the onset of clinical symptoms [192]. Besides 
antibodies, no further identification of entry inhibitors specifically targeting RABV G has been 
accomplished, though a couple of compounds have been identified to competitively inhibit 
RABV entry by interacting with its host receptors. One such compound derived from snake 
venom has been shown to prevent RABV entry, however, it irreversibly binds to AChR and 
subsequent studies have not been able to replicate this result [193]. Furthermore, RABV G 
interacts with multiple ubiquitous host receptors suggesting that direct targeting of G is a 
superior antiviral strategy. The antigenic sites discovered through antibody adaptation studies, or 
the more conserved stalk region of G are possible targets for small-molecules that would 
alleviate the cost barrier and cold-chain requirement [188, 194-197].  
As a core constituent of the RdRP heterocomplex, L is organized into highly conserved 
enzymatic domains that specialize in RNA synthesis, mRNA capping and mRNA methylation 
(Figure 24 A,B) [198]. Pyrimidine analog, ara-C was shown to partially inhibit viral replication, 
though only at levels that completely abrogated host DNA synthesis [199]. Another pyrimidine 
analog, 6-Azauridine that showed virus reduction in vitro, however, was only efficacious against 
lab adapted RABV strains [200]. Viral inhibition was observed with purine analogs vidarabine 
and (S)-DHPA but the mechanism of inhibition was found to prevent both host and viral RNA 
synthesis [201]. In an effort to reduce cytotoxicity and enhance specificity, ribavirin analogs 
were also tested for efficacy against RABV but were found to only be potent against the vaccine 
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strain. Favipiravir, a broad-spectrum RdRP inhibitor, was also tested for efficacy against RABV. 
When tested against mice, there was a 50% survival rate, and the survivors developed 
debilitating limb paralysis [202, 203]. Furthermore, Favipiravir (T-705) has teratogenic and 
embryotoxic properties that also make it a less attractive drug candidate [35].  
 
Figure 24. Rabies virus large protein A) Schematic diagram depicting the domain 
organization of RABV large protein (L). The GDN polymerization motif is in red. The 
polyribonucleotidyltransferase (PRNTase) is in blue. The methyltransferase (MTase) is in cyan. 
The phosphoprotein (P) binding region is purple. Conserved regions (CR) of the non-segmented 
negative-sense RNA viruses are labelled CR I -VI. B) Surface representation of the RABV L 
generated by homology modelling based on the coordinates reported for the closely related VSV 
L structure. Below is a zoomed in ribbon representation of the GDN motif responsible for 
polymerase activity in red. [204-207] (Figure from Du Pont et al., 2019 [127] 
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Table 2. Direct-acting RABV inhibitors 
Compound Target EC50 (uM) CC50 (uM) SI (CC50/EC50) Ref. 
Ketamine vRNA 
Synthesis 
922.93 ± 68.48 
 
3010.69 ± 171.26 
 
3.3 [164, 207] 
Ribavirin de novo purine 
synthesis 
18.55 >200 >10 [208] 
EICAR de novo purine 
synthesis 
0.90 >200 >200 [208] 
EICNR de novo purine 
synthesis 
3.80 >200 >50 [208] 
Favipiravir vRdRp 32.4 >2500 >1000 [202, 209] 
*Table from Du Pont et al., 2019 [126] 
1.3.5 Aim of Dissertation Chapter 2 
 
Figure 25  Flow chart detailing HTS compound hit compound identification and counter-
screening strategies employed for hit compound discovery and verification. Concentrations of 
compound are detailed, as well as hit progression and removal criteria. 
 
The cold-chain requirement, high cost, and lack of effectiveness against emerging 
zoonotic lyssaviruses of the current RABV PEP treatment has underscored an unmet need for 
antiviral drug discovery. To date, none of the small-scale screening campaigns against RABV 
have come close to presenting an alternative to current treatment that is safe, efficacious, BBB 
permeating, and specific to RABV.  
The primary aim of this study was to address this growing clinical need by employing a 
high-throughput screening (HTS) campaign using a novel BSL-2 compatible RABV reporter 
virus that is limited to single-cycle infection. This reporter virus was tested in 384-well format 
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against multiple in-house open-discovery screening compound libraries specifically curated to 
exclude compounds with problematic chemistry. The mechanism of action and therapeutic 
potential of hit candidates were characterized with systematic counter and orthogonal screens. 
The efficacy of confirmed hits was also tested in the context of multiple replication competent 
RABV reporter strains. One viable hit, GRP-60367, was further characterized for mechanism of 
action and resistance profiling (Figure 26).  
1.3.6 Chapter 2 Materials and Methods 
Cells: Human bronchial epithelial cells (BEAS-2B; ATCC CRL-9609), human 
embryonic kidney cells (HEK-293T; ATCC CRL-3216), baby hamster kidney cells stably 
expressing T7 polymerase (BSR-T7/5) and African green monkey kidney epithelial cells (Vero; 
ATCC CCL1-81) were maintained at 37oC in 5% CO2 in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 7.5% fetal bovine serum. The BSR-T7/5 cell line was 
supplemented with G-148 every 5th passage and cells were transfected using GeneJuice 
(Novagen) according to the manufacturer’s instructions.  
Molecular Biology: Point mutations of escape mutants from adaptations were introduced 
via the QuickChange mutagenesis PCR protocol. Recombinant viruses were produced by 
introduction of point mutations in a shuttle vector that used restriction sites mluI and NheI to 
transpose the G ORF to a vector containing full length genomic DNA.   
Compounds:The screening set contained a compilation of commercially available 
libraries (ChemDiv, 30,000 compounds; ChemBridge, 100,000 compounds; and proprietary 
collections from the Emory institute for drug development, 1,155 compounds; and Kansas 
University,11,520 compounds) that are specifically curated against compounds with pan-assay 
interfering or other undesirable chemical structures. The compounds from each library were 
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dissolved in dimethyl sulfoxide (DMSO) to a concentration of 10 µM and stored at -80oC. All 
HTS electronic compound management, data storage, and data analysis was performed using the 
MScreen software package. Prior to screening, all compounds were inventoried in Mscreen and 
reformatted into barcoded 384-well plates using a Nimbus96 liquid handler (Hamilton Robotics). 
Each 384-well daughter plate consists of positive (cycloheximide) and negative (DMSO) 
controls in a checkerboard pattern on the two lateral columns on both sides of every plate.  
HTS Protocol: BEAS-2B cells (3.5x103/well) were seeded in barcoded 384-well white 
wall/clear bottom plates using a MultiFlo automated dispenser (BioTeK) equipped with dual 10 
µl peristaltic pump manifolds followed by collection (150 x g for 90 sec at 25oC) and incubated 
for 14 hours at 37oC in 5% CO2. Compound addition for a final concentration of 5 µM (20 
nl/well) was performed by the Nimbus96 liquid handler outfitted with a high-density pintool 
(V&P Scientific) attached to the pipetting head. Both source and assay plates were read by the 
Nimbus96 unit at the time of compound stamping. Co-infection of recRABVDG-SBNG 
(multiplicity of infection (MOI) = 0.01) at 10 µl/well was performed using a Multiflo dispenser 
followed by spin collection and incubation at standard conditions for 48 hours post-infection. 
Plates were loaded into an H1 synergy plate reader (BioTek) with a stacker and identified with 
an integrated barcode reader, that also automatically injected nano-Glo substrate (10 µl/well) and 
bioluminescence was recorded 3 minutes after substrate addition.  
HTS Data normalization and Hit identification: Data analysis was performed using 
raw data imported from the Nimbus96 (source and assay barcode maps) and plate reader 
bioluminescence readouts to the Mscreen software package. Normalized relative inhibition 
values were calculated by dividing the results by the difference between positive and negative 
plate control means. Robust z-scores were calculated by the formula: robust z-score = (Si – 
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median (Sall))/MAD(Sall) and MAD(Sall) = 1.4826 × median (|Si – median (Sall)|) (where Si = 
individual compound value, and Sall= values of all compounds on the plate).  Hit candidates were 
defined as compounds with ³ 70% inhibition of normalized signal intensity against 
recRABVDG-SBNG, a robust z-score ³2.0, and <35% inhibition against RSV-FF, WSN-nano, 
and HPIV-3-nano. Hit candidates were also queried using the SciFinder database package to 
determine known bioactivity. 
Automated dose-response counter-screening: BEAS-2B cells (3.5 x 103 cells/well) 
were seeded in barcoded white wall/clear bottom 384-well plates using a MultiFlo automated 
dispenser as described above. The Nimbus96 unit was used to prepare 3-fold dilutions hit 
compounds (0.078 – 10 µM) in barcoded 384-well plate format for subsequent dose-response 
and cytotoxicity counter-screening. BEAS-2B cells (3.5 x 103/well) were seeded in barcoded 
white wall/clear bottom 384-well plates using a MultiFlo automated dispenser as described 
above, then stamped with the counterscreen plates using the high-density pin tool. Cell viability 
in the presence of compound was tested using PrestoBlue substrate (5 µl/well) 
(LifeTechnologies) 48 hours post compound addition. Addition of PrestoBlue was performed 
according to the manufacturer’s instructions and read using the H1 synergy plate reader 
(excitation at 560 nm, emission at 590 nm and gain of 85).  
Dose response reporter Assays: The Nimbus96 unit was used to transfer three-fold or 
five-fold serial dilutions (as indicated by the Figure) of hit candidate compounds to 96-well 
plates seeded with BEAS-2B, 293T, or BSR-T7/5 cell lines (1.5 x 104 cells/well). Controls 
included four positive (1 mg/ml cycloheximide) and four negative (0.05% DMSO) wells on each 
plate. The cells were infected with recRABVDG-SBNG (MOI = 0.1) using the MultiFlo 
dispenser and bioluminescence reporter activity was read by the H1 synergy plate reader 48 
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hours post infection. Dose-response inhibition curves were generated according to the formula: 
% inhibition = (XSample – XMin)/(XMax – XMin) × 100, with XMin representing the average of the 
positive and XMaxthe average of the negative control wells and the Prism (GraphPad) nonlinear 
regression function with a four-parameter regression slope was applied to determine 50% 
effective concentration (EC50) of each hit compound. All dose-response activity assays were 
performed in 3 independent repeats. 
Kinetic cell-cell fusion assay: BEAS-2B cells (1.5 x 105 cells/well) were cotransfected 
with 1.0 µg RABV-G or RABV-Gescapemutant expression plasmids and 0.5 µg DSP1-7 expression 
plasmid. DSP8-11 was transfected independently. Cells were harvested 24 hours post-
transfection and reseeded with equal parts of G and DSP1-7 containing cells with DSP8-11 
containing cells in a 96-well plate to a total of 4 x 103 cells/well.  Cells were pretreated with 
viviren substrate 4 hours post-reseeding for 1.5 hours according to the manufacturer’s 
instructions. Fusion was triggered by the addition of 100 µl of DMEM with pH=6.0 and ViviRen 
signal was measured by the Cytation5 cell imaging multimode reader (BioTek) every 30 minutes 
for 4 hours. Values are shown as percent normalized to RABV-G and are based on 3 independent 
repeats.  
Virus Adaptation: BEAS-2B cells were infected with recVSV-GFP-RABV-G with an 
MOI of 0.1 TCID50 units/cell and incubated for 30 min at 37oC 5% CO2 before addition of 1.1 
µM of GRP-60367. Fresh BEAS-2B cells were infected with 10-fold dilution of supernatant-
associated virions every two days with gradual increase of compound until 100 µM was 
tolerated. Total RNA was extracted from 8 individually adapted clones and cDNAs were 
generated using random hexamer primers, and the G protein ORF was amplified and subjected to 
Sanger sequencing. Confirmed escape mutations were introduced to G protein expression 
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plasmids and also rebuilt into the recVSV-GFP-P plasmid background for recovery of escape 
mutants in the context of full-length virus.   
Recombinant Virus Recovery: RecVSV-RABV-G were recovered as previously 
described [211]. Briefly, plasmid vectors expressing  VSV-N (0.5 µg), VSV-P(0.4 µg), VSV-L 
(0.2 µg) and plasmid with genomic recVSV-RABV-GFP or recVSV-RABV-G-GFP mutants (1.0 
µg) were transfected in BSR-T7/5 cells (2.5 x 105 cells/well) and incubated at 37oC and 
monitored for viral particle formation by visualized GFP signal. Viral supernatant was overlaid 
onto fresh Vero-E6 cells infection was allowed to proceed and viral supernatant was collected 
and TCID50 was quantified by GFP signal. 
Surface biotinylation, SDS-PAGE and immunoblotting: BSR-T7/5 cells were seeded 
in a 6-well plate (4 x 105 cells/well) and transfected with 1 µg of RabV G or RABV G adaptation 
mutants.  Twenty-four hours post-transfection cells were washed twice in cold PBS, cells were 
then biotinylated with 0.5 mg/ml sulfosuccinimidyl-2-(biotinamido)ethyl-1,3-dithiopropionate 
(Pierce) for 30 minutes, quenched with  1M Tris (pH 7.5), and washed three times with cold PBS 
prior to lysis in RIPA buffer (1% sodium deoxycholate, 1% nonidet P-40, 150 mM NaCl, 50 mM 
Tris-Cl at pH 7.2, 10 mM EDTA, 50 mM NaF, and protease inhibitors (Pierce)). Strepdavidin 
bead slurry was added to each cleared lysate sample (14,000 rpm for 30 minutes at 4oC) and 
incubated on a rotor for 2 hours in 4oC. Washed precipitates and total lysates were fractioned by 
SDS-PAGE and transferred onto a PVDF membrane by semi-dry transfer. Proteins were detected 
by immunoblot with anti-RABV G antibodies derived from rabbit sera followed by 
chemiluminescent detection with a ChemiDoc digital imaging system (Bio-RAD).  
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1.3.7 Chapter 2 Results 
1.3.7.1 HTS Protocol Validation and HTS of RABV-DG-nanoLuc 
One of the hurdles for large-scale anti-RABV drug discovery continues to be the 
requirement for BSL-2+ containment. In order to overcome this obstacle, we designed a first-in-
class RABV reporter strain that replaces the RABV G protein ORF with that of nano-luciferase 
(RABV-DG-nanoLuc) (Figure 26A). RABV-DG-nanoLuc was rescued via co-transfection of 
genome-encoding plasmid with helper plasmids encoding for N, P, and L proteins in vaccine 
strain SAD-B19 G-expressing starter cells. The resultant virus was a recombinant pseudotyped 
RABV reporter strain that is limited to single-cycle infection.  
 
Figure 26 Identification of a small-molecule hit specific against RABV A) Representation 
of standard RABV (top) and RABV-DG-nanoLuc (bottom) B) Validation assay of vehicle treated 
RABV-DG-nanoLuc compared to treatment with broad-spectrum DHODH inhibitor JMN3-003 
003 at 0.5xEC50 and 10xEC90 concentrations in 384-well format. C)  Rocket plot of compound 
inhibition vs. robust Z-score for hit compound identification. Red dashed line signifies cut-off 
criteria for hit candidates (>70% RABV inhibition and Z-score >2.0). Cytotoxic (red), 
nanoblocking compounds (yellow), RABV specific compounds (green) and hit candidate GRP-
60367 (blue) are indicated in the zoomed in portion of the graph. D) Chemical structure of hit 
candidate GRP-60367.  
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In order to validate RABV-DG-nanoLuc in the context of our previously established 
screening protocol [212, 213], we first tested the robustness of the protocol in 96-well plate 
format. Three reference plates were seeded with BEAS-2B cells and organized into alternating 
columns of vehicle (no inhibition (max)), intermediate (0.5 x EC50), or sterilizing concentrations 
(10 x EC90) of the broadly active polymerase inhibitor JMN3-003 [214] (Figure 26B). In order 
to emulate HTS conditions, fully automated cell seeding, liquid handling, and plate detection 
equipment was utilized. This assay served to test the ability of the protocol to reliably detect viral 
inhibition and allowed us to quantitatively assess signal-to-background ratios, Z’ values, and 
coefficients of variation (CV). Forty hours post-infection, the luciferase signal was between 
71.6-82.0-fold of background, the Z’ value was 0.5, and the CVs averaged to 16%.  All of these 
values were within acceptable and established thresholds, which prompted us to continue with 
automated HTS to search for inhibitors of RABV [212, 215]. 
HTS screening was accomplished by miniaturizing our assay to 384-well format and 
testing approximately 150,000 compounds from our highly curated in-house screening library for 
RABV-DG-nanoLuc inhibition. All compounds were tested at a final concentration of 5 µM. For 
hit candidate selection, we implemented our standardized bidirectional statistical approach that 
compares control-dependent % inhibition by plate (>70% inhibition) and robust z-score (z-score 
>2.0) [212, 213, 215]. This approach yielded a total of 386 hit candidate compounds. Frequently 
occurring hits were further filtered out based on activity in previous HTS screens. We scanned 
our database using the MScreen software to identify compounds with 35% inhibition or greater 
against previously screened viruses: WSN-nanoLuc (-18 compounds), HPIV-3-nanoLuc (-279 
compounds), and RSV-FireSmash (-39 compounds) (Figure 26C) [213]. The remaining 50 
compounds were counter-screened in 384-well format to establish reproducible efficacy, tested 
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for cytotoxicity and target virus-specificity in 3-fold dilutions with a range of 20 µM to 0.009 
µM. Only one of the hits, GRP-60367 (Figure 27D), consistently exhibited promising nanomolar 
dose-dependent virus inhibition, RABV specificity, and had no significant cytotoxicity.  
1.3.7.2 Determining the mechanism of action of GRP-60367 
Strong viral inhibition by GRP-60367 was confirmed in several established human cell 
lines, returning EC50 concentrations of 3.0 nM, 2.0 nM, and 51.8 nM in BEAS-2B, HEp2, and 
HEK-293T cells, respectively (Figure 27A). There was no observable cytotoxicity in all three 
cell lines when the compound was added up to a concentration of 300 µM, yielding a selectivity 
index (SI, CC50/EC50) >16,000 (Figure 27A). In order to test the indication spectrum of GRP-
60367 and its efficacy in neuronal cells, we pseudotyped RABV-DG-nanoLuc with the G 
proteins of two RABV strains: the mouse-adapted neurotropic N2c strain [216] and a bat-derived 
Ef strain [217] . There was no observable cytotoxicity in the neuronal cell line N2a (Figure 27B, 
gray). The screening virus exhibited a slightly increased EC50 of 0.43 µM. The viruses 
pseudotyped with the EF and N2c G proteins exhibited even higher EC50 values of 2.71 µM and 
3.35 µM respectively (Figure 27B). Previous studies have shown SAD-B19, our screening 
strain, to be poorly neurotropic as compared to N2c [218]. The difference in infectivity of N2a 
cells has been attributed to differences in propagation and selection pressure in tissue culture cell 
lines [219]. The decline in potency against the neurotropic N2c and EF strains may result from 
the slower kinetic with which SAD-B19 G infects neuronal cell lines, while ease of entry by the 
neurotropic EF and N2c G proteins more easily evades compound binding.  
In order to mechanistically characterize GRP-60367, we employed a time-of-addition 
(TOA) that allowed us to ascertain which step of the viral life cycle the compound was blocking. 
Virucidal activity of GRP-60367 was most effective when added at the time of infection, 
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however, compound efficacy steadily declined each hour of addition thereafter and lost major 
efficacy 2 hours post infection (Figure 27C). This TOA profile is consistent with previously 
described entry inhibitors [213, 220-222]. Recently identified RABV entry inhibitor, tryphostin 9 
similarly exhibited gradual decline in efficacy that eventually plateaued after 7 hpi, and contrasts 
with polymerase inhibitor TOA profiles, which continue to have efficacy up to 9 hpi [213].  
 
Figure 27. Mechanistic characterization of GRP-60367 A) dose-response inhibition 
curves of GRP-60367 within several cell lines: BEAS-2B (black, EC50 3.0 nM), HEp2 (red, EC50 
2.0 nM), and HEK-293T (blue, EC50 51.8 nM). Cell viability determined by Prestoblue substrate 
after 3 day incubation with 300µM concentration of GRP-60367 in multiple cell lines: BEAS-2B 
(black), HEp2 (blue), and HEK-293T (red) B) Determination of efficacy of GRP-60367 against 
G proteins from multiple RABV strains including the screening strain (SAD, black, EC50 2.15 
µM), a bat-derived strain (EF, red, EC50 0.443 µM), and a mouse adapted neuronal strain (N2c, 
blue, EC50 3.55 µM). Cytotoxicity of GRP-60367is denoted in green. C) Time of addition of 
GRP-60367 (10 µM) at specified times to determine efficacy over time post infection with 
RABV-DG-nanoLuc (red) and VSV-nanoLuc (black) in BEAS-2B cells. 
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1.3.7.3 Resistance Profiling by Viral Adaptation 
In order to generate a resistance profile for GRP-60367, we exchanged VSV G for RABV 
G in a fully replication competent recombinant VSV virus genome background that also 
harbored GFP in a pre-L ORF position (Figure 28A). This virus was inhibited in a dose-
dependent manner by GRP-60367 with an EC90 of 1.1 µM (Figure 28B). Adaptation to GRP-
60367 was achieved through gradual increase of compound over time, until a concentration of 
110 µM (100 x EC90) was tolerated (Figure 28C). RT-PCR followed by Sanger sequencing of 
eight independently adapted lineages revealed several candidate mutations that mapped to the 
extracellular domain of G, and one early stop mutation in the G cytoplasmic domain (Figure 
28D). 
 
 
 
 
 
 
 
 
 
  
Figure 28. Adaptation of recVSV-GFP-RABVG to GRP-60367 A) schematic representation of recVSV-
RABV-G without (top) and with GFP ORF (bottom). B) Dose-response inhibition of recVSV-GFP-RABV-G in 
the presence of GRP-60367 C) Graphical representation of adaptation strategy. C) Mutations within 8 
independently adapted viral lineages occurring within the G protein. Red amino acids represent observed 
mutations. 
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Using a homology model generated based on the crystal structure of VSV G, all 
mutations were mapped to the fusion domain of RABV G (Figure 29A). Most adapted lineages 
emerged with a single point mutation located within the G fusion loops at amino acid Y138 that 
resulted in a change to serine, cysteine, or asparagine. Of the three point mutations, Y138S 
occurred the most frequently while Y138C and Y138N were found in one lineage each. 
Exchange of the resident tyrosine for these residues indicates a strong preference for polar 
groups within the fusion loops of G.  The predominant Y138S is most likely favored due to a 
common hydroxyl group provided by the serine. We also identified two additional point 
mutations within the fusion loops located further upstream in the G polypeptide: Y96S and V97I. 
All mutations are relatively benign and most likely conferred resistance by maintaining the polar 
or hydrophobic micro-environment while at the same time indirectly reducing compound affinity 
through long-range effects [220]. We also detected a cytosine to thymine mutation within the 
intracellular domain of G that was located downstream of the transmembrane domain and 
resulted in an early stop mutation (R485*) and thus a truncated G protein.  
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Figure 29. A) Homology model of RABV G trimer based on the solved VSV G structures 
for pre-fusion (top) and post-fusion (bottom) (PDB: ) Each monomer is individually colored 
(pink, gold, and lavender). Residues mutated from adaptation are indicated as colored spheres: 
Y138 (blue) V98 (green) and V97 (pink). B) Surface biotinylation of standard G and G escape 
mutants. G proteins were detected using aRABV-G and GAPDH was used as the loading 
control. Transferrin was detected for affirmation of biotinylation success. Relative cell surface 
expression as compared to standard G is graphically represented ±SD and based on 3 
independent biological repeats. C) Kinetic fusion assay of G protein mutants based on renilla 
luciferase readout over four hours with >3 biological repeats.  D) Kinetic fusion assay of G 
protein adaptation mutants incubated with GRP-60367 (20µM) over a four-hour period >3 
biological repeats.  Both kinetic fusion assays are expressed as percent of standard G renilla 
luciferase units at the four-hour timepoint. All statistical analyses through one-way ANOVA with 
Tukey’s post hoc multiple comparison test. (NS, not significant; *, p ≤ 0.1; ****: p ≤ 0.0001). 
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To further investigate their impact on G expression, we introduced each mutation into a 
standard G ORF After transient expression and subsequent surface biotinylation, we used 
densitometry of western blot protein bands to quantitatively compare relative cell membrane 
steady state levels (Figure 29B). All mutants, with the exception of R485*, were not 
significantly different from standard RABV G in cell surface expression. Interestingly, R485* 
had lower total expression, and its surface expression remained only 50% as compared to 
standard G. This result suggests inherent misfolding and internalization of this particular G 
mutant. Lowered expression of G has been shown to have little impact on pathogenicity or 
neurovirulence and part of the success of the current vaccine strain is overexpression of G to 
enhance antibody recognition [223]. For example, the higher neurovirulence of N2c as compared 
to B2c, a closely related and less pathogenic variant, is related to decreased surface G proteins 
[216, 223-225]. From these studies we can postulate that the R485* mutation causes long-range 
or direct changes in the compound binding pocket, yet most likely has very little impact on viral 
fitness.  
Because the expression profiles exhibited by the other mutants (Y138C, Y138N, Y138S, 
Y96S, and V97I) rule out overexpression of G as a means of escape, we investigated the fusion 
rates of the mutants using a Renilla split-luciferase reporter assay. This assay relies on the 
reconstitution of bioactivity from two halves of the Renilla luciferase protein that can only trans-
complement after a fusion event [29, 220, 226-228]. This was accomplished by transiently co-
transfecting G mutants with an N-terminal Renilla fragment, while a second population of cells 
was independently transfected with the C-terminal fragment. After cell mixing and low pH 
induction, Renilla luciferase activity was monitored for four hours with readouts every 15 
minutes using the Cytation5 automated high content imager (Figure 29C, D). Only Y138S had 
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heightened fusion rates in the absence of compound at the four-hour timepoint, while the other 
mutants were not phenotypically distinct from standard G. In the presence of 20 µM compound, 
the Y138S mutant still had an accelerated fusion rate, and the Y138N and V97I mutations were 
not significantly hindered by compound as compared to standard G (Figure 29D). Enhancement 
of the fusion rate enables the Y138S mutant to escape by faster triggering of G protein fusion, 
thus narrowing the opportunity for compound interference. This mechanism of escape has been 
previously described for other viruses resistant to entry inhibitors and is often attributed to 
decreased, structural stability of the fusion machinery [220, 229]. Interestingly, the other 
mutations at Y138, Y96, and V97I did not result in an altered fusion rate (Figure 29D). This 
indicates that these mutants employ an alternative mode of escape, most likely a shift in the G 
structure that disrupts compound affinity. 
 
1.3.8 Chapter 2 Discussion 
The difficulty of access and cold-chain requirement of current RABV PEP treatment have 
underscored the unmet need for expanded therapeutic options against rabies disease. However, 
current containment requirements of RABV and lack of discernable cell culture cytopathic effect 
pose a challenge for the implementation of large-scale drug discovery efforts.  
To address these obstacles, we generated a pseudo-typed Nano luciferase-expressing 
reporter RABV strain that is limited to single-cycle infection. RABV-DG-nanoLuc provides the 
distinct advantage of enabling quantitative assessment of viral inhibition in a BSL-2 laboratory 
setting. With our reporter strain, we successfully executed the first-ever high-throughput 
screening campaign targeting RABV with our open-discovery library comprised of over 150,000 
small-molecule compounds.  
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Our HTS screen identified a novel first-in-class RABV inhibitor, GRP-60367, that 
demonstrated low nanomolar antiviral activity in multiple cell lines, including a neuronal cell 
line, without observable toxicity. Mechanistic characterization of GRP-60367 revealed that it 
blocks an early step in the viral lifecycle based on the dramatic loss of compound potency 2 
hours post-infection based on time of addition studies. The role of GRP-60367 in blocking viral 
membrane fusion was further confirmed by engineering a cell-to-cell fusion assay that employed 
a dual-split luciferase reporter to quantify fusion events over time.   
Direct-counter screening of GRP-60367 revealed dose-dependent inhibition of both 
mouse and bat RABV challenge strains in the micromolar range. However, the inhibition 
observed was 10-fold less potent as compared to the efficacy against the vaccine-derived 
screening strain. The decreased effectiveness of GRP-60367 could be attributed to strain-
dependent variations in glycoprotein conformation that directly affect the structure of the 
candidate compound binding pocket. However, the low toxicity and chemical profile of GRP-
60367 potentiates it as an ideal lead candidate scaffold for future structure-activity relationship 
optimization to obtain a broader indication spectrum. 
Resistance profiling of GRP-60367 escape mutants revealed two mechanisms of escape. 
The mutants, Y138S, Y138N, and V97I, all exhibited a hyperactive fusion rate as compared to 
standard RABV G. Previously, several critical residues in RABV G encompassing residues 392-
396 have been identified to regulate fusion activity. However, none of the escape mutations 
emerging in our virus adaptation study have been previously implicated in this role [188, 194-
196, 230, 231]. Homology modeling of RABV G based on the solved VSV G structure revealed 
that residues Y96, V97, and Y138, reside within the tips of the fusion loops, which are released 
to anchor into the target membrane [232]. Though Y96S seems to have little effect on the fusion 
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kinetics, the enhanced fusion rate of the Y138S mutation suggests a dominant role in 
determining the fusion rate. Synonymous mutations of analogous fusion peptides of several 
viruses of Paramyxoviridae have also demonstrated accelerated fusion rates [233-236]. As 
with Paramyxoviridae, it is possible that the residues identified here may also regulate the 
kinetic barrier for membrane fusion and that the escape mutations destabilize G to promote 
triggering of the fusion machinery. Mutations within the fusion loops of closely related VSV 
have resulted in abrogated fusion activity by changing side chains to hydrophobic amino acids. 
These mutations caused destabilization of the interaction between fatty acid chains and head 
groups of lipids [191, 232, 237, 238]. In contrast, the acquired mutations from GRP-60367 may 
stabilize the lipid interaction to facilitate pore formation.  
Interestingly, mutants Y138C, Y96S, and the early stop mutation demonstrated similar 
fusion rates compared to standard G despite proximity to the previous mutations. Modification of 
these residues without resulting in altered entry kinetic implicate this region either as the primary 
compound binding site or that these mutations directly alter the binding pocket. Several N-linked 
glycosylation sites containing the motif Asn-X-Ser/Thr were previously identified in RABV G 
[239]. Mutation of residue Y96 to serine completes this motif for an upstream asparagine. 
Therefore, it is tempting to postulate glycosylation as a means of escape, especially since the 
introduction of N-glycans can improve virus production for street RABV in neuronal cell lines 
[240, 241]. Truncation of the cytoplasmic tail of gp41 of HIV-1 has been shown to have long-
ranging conformational effects that modulate ectodomain antigenicity at the cost of surface 
expression. Although surface expression of the RABV G truncated mutant was similarly 
decreased, it appeared not to affect viral entry. Lowered expression of G has little impact on 
pathogenicity or neurovirulence, and part of the success of the current vaccine strain is 
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overexpression of G to enhance antibody recognition [223]. For example, the higher 
neurovirulence of N2c as compared to B2c, a closely related and less pathogenic variant, is 
connected to decreased surface G proteins [126, 216, 223-225]. Based on our data, we can 
postulate that the R485* mutation causes long-range changes to the compound binding pocket in 
the ectodomain without affecting viral fitness. 
 Here we have provided a proof-of-concept framework for future anti-RABV HTS 
campaigns, developed a reliable and safe RABV reporter strain, and identified a potent and 
newly characterized first-in-class RABV entry inhibitor that emerged from our screen. All of the 
mutations identified from the adaptation studies have not been previously characterized by 
epitope mapping, suggesting GRP-60367 occupies a novel druggable pocket [194-196, 231, 
242]. Although the exact mechanism of inhibition by GRP-60367 remains unclear, it was 
instrumental in identifying Y138 as a critical residue for entry mechanics. Therefore, GRP-60367 
is a viable tool that can lead to further mechanistic understanding of class III fusion protein entry 
paving the way for better informed drug discovery against RABV.  
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2 Conclusions 
2.1 Chapter 1 Conclusions 
 We have advanced the current understanding of the underlying mechanism of 
paramyxovirus RdRp movement along the encapsidated genome, a previously poorly understood 
process, by identifying and characterizing the interactions between the core RdRP constituents. 
This discovery was accomplished by identifying two microdomains within P for L binding. One 
microdomain is a highly conserved region proximal to the oligomerization domain (OD), that we 
predicted to serve as an anchor for L. The second contact point consists of a previously 
unassigned face of the PXD triangular prism. Our innovative approach of using functional trans-
complementation assays between P mutants allowed us to determine the stoichiometric 
relationship between PXD:L and PXD:MoRE interactions, and enabled us to appreciate a 
regulatory role of PXD in RdRP negotiation of the viral template. Based on these discoveries, we 
have proposed a novel mechanistic model that posits RdRP advancement along the genomic 
template regulated by PXD competition for L binding. The discovery of this dynamic interaction 
of PXD with L has not only furthered our understanding of how the viral polymerase negotiates 
and regulates advancement along the genomic template, but also highlighted a potential 
druggable target. Because of the conserved structural homology between the polymerase 
assemblies of the Paramyxoviridae, we propose that our discovery of the PXD:L interface could 
serve as a valid antiviral platform for drug development against emerging viruses within the 
family, such as zoonotic NiV, against which currently no vaccine or antiviral treatment exists. 
2.2 Chapter 2 Conclusions 
We have successfully developed and implemented an innovative high-throughput cell-
based drug screening protocol using a first-in-class reporter strain of RABV that is capable only 
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of a single round of infection. From this screen, we have identified a novel direct-acting RABV 
entry inhibitor, GRP-60367, that exhibits low nanomolar efficacy with a CC50 >300 mM in all 
cell lines tested. Resistance profiling revealed a previously uncharacterized amino acid, Y138, 
that serves as a determinant for RABV G fusion kinetics. GRP-60367 may serve as a much-
needed innovative molecular point of entry for better characterization of the mechanics of 
currently still understudied type III viral fusion proteins 
 
 
  
90 
3 REFERENCES 
1. Lamb, R.A., Mononegavirales, in Fields Virology, D.M.K.P.M. Howley, Editor. 2013, 
Lippincott Williams & Wilkins: Philadelphia, PA. p. 880-884. 
2. Smallwood, S. and S.A. Moyer, Promoter analysis of the vesicular stomatitis virus RNA 
polymerase. Virology, 1993. 192(1): p. 254-63. 
3. Iverson, L.E. and J.K. Rose, Localized attenuation and discontinuous synthesis during 
vesicular stomatitis virus transcription. Cell, 1981. 23(2): p. 477-84. 
4. Ogino, T. and A.K. Banerjee, Unconventional mechanism of mRNA capping by the RNA-
dependent RNA polymerase of vesicular stomatitis virus. Mol Cell, 2007. 25(1): p. 85-97. 
5. Ogino, T. and T.J. Green, RNA Synthesis and Capping by Non-segmented Negative Strand 
RNA Viral Polymerases: Lessons From a Prototypic Virus. Front Microbiol, 2019. 10: p. 
1490. 
6. Furuichi, Y. and A.J. Shatkin, Viral and cellular mRNA capping: past and prospects. Adv 
Virus Res, 2000. 55: p. 135-84. 
7. O'Brien, K.L., T. Nolan, and S.W.o. Rabies, The WHO position on rabies immunization - 
2018 updates. Vaccine, 2018. 
8. Angelo, K.M., et al., Spread of Measles in Europe and Implications for US Travelers. 
Pediatrics, 2019. 144(1). 
9. Guerra, F.M., et al., The basic reproduction number (R0) of measles: a systematic review. 
Lancet Infect Dis, 2017. 17(12): p. e420-e428. 
10. Patterson, J.B., M. Manchester, and M.B. Oldstone, Disease model: dissecting the 
pathogenesis of the measles virus. Trends Mol Med, 2001. 7(2): p. 85-8. 
11. Gokiert, J.G. and W.E. Beamish, Altered reactivity to measles virus in previously 
vaccinated children. Can Med Assoc J, 1970. 103(7): p. 724-7. 
12. Rammohan, K.W., H.F. McFarland, and D.E. McFarlin, Subacute sclerosing 
panencephalitis after passive immunization and natural measles infection: role of 
antibody in persistence of measles virus. Neurology, 1982. 32(4): p. 390-4. 
13. Norrby, E. and K. Kristensson, Measles virus in the brain. Brain Res Bull, 1997. 44(3): p. 
213-20. 
14. Angius, F., et al., Analysis of a Subacute Sclerosing Panencephalitis Genotype B3 Virus 
from the 2009-2010 South African Measles Epidemic Shows That Hyperfusogenic F 
Proteins Contribute to Measles Virus Infection in the Brain. J Virol, 2019. 93(4). 
15. Mathieu, C., et al., Measles Virus Bearing Measles Inclusion Body Encephalitis-Derived 
Fusion Protein Is Pathogenic after Infection via the Respiratory Route. J Virol, 2019. 
93(8). 
16. Kweder, H., et al., Measles Virus: Identification in the M Protein Primary Sequence of a 
Potential Molecular Marker for Subacute Sclerosing Panencephalitis. Adv Virol, 2015. 
2015: p. 769837. 
17. Mina, M.J., et al., Long-term measles-induced immunomodulation increases overall 
childhood infectious disease mortality. Science, 2015. 348(6235): p. 694-9. 
91 
18. Centers for Disease, C. and Prevention, Postexposure prophylaxis, isolation, and 
quarantine to control an import-associated measles outbreak--Iowa, 2004. MMWR 
Morb Mortal Wkly Rep, 2004. 53(41): p. 969-71. 
19. McLean, H.Q., et al., Prevention of measles, rubella, congenital rubella syndrome, and 
mumps, 2013: summary recommendations of the Advisory Committee on Immunization 
Practices (ACIP). MMWR Recomm Rep, 2013. 62(RR-04): p. 1-34. 
20. Gastanaduy, P.A., et al., Public health responses during measles outbreaks in elimination 
settings: Strategies and challenges. Hum Vaccin Immunother, 2018. 14(9): p. 2222-2238. 
21. Barnard, D.L., Inhibitors of measles virus. Antivir Chem Chemother, 2004. 15(3): p. 111-
9. 
22. Jeulin, H., et al., In vivo antiviral activity of ribavirin/alpha-cyclodextrin complex: 
evaluation on experimental measles virus encephalitis in mice. Int J Pharm, 2008. 357(1-
2): p. 148-53. 
23. Pal, G., Effects of ribavirin on measles. J Indian Med Assoc, 2011. 109(9): p. 666-7. 
24. Barnard, D.L., et al., Inhibition of measles virus replication by 5'-nor carbocyclic 
adenosine analogues. Antivir Chem Chemother, 2001. 12(4): p. 241-50. 
25. Barnard, D.L., et al., Coumarins and pyranocoumarins, potential novel pharmacophores 
for inhibition of measles virus replication. Antivir Chem Chemother, 2002. 13(1): p. 39-
59. 
26. Zhang, N., et al., in vitro inhibition of the measles virus by novel ring-expanded ('fat') 
nucleoside analogues containing the imidazo[4,5-e]diazepine ring system. Bioorg Med 
Chem Lett, 2002. 12(23): p. 3391-4. 
27. Elia, G., et al., In vitro efficacy of ribavirin against canine distemper virus. Antiviral Res, 
2008. 77(2): p. 108-13. 
28. Jeulin, H., et al., Effective ribavirin concentration in mice brain using cyclodextrin as a 
drug carrier: evaluation in a measles encephalitis model. Antiviral Res, 2009. 81(3): p. 
261-6. 
29. Sun, A., et al., Nonpeptide inhibitors of measles virus entry. J Med Chem, 2006. 49(17): p. 
5080-92. 
30. Sun, A., et al., Non-nucleoside inhibitors of the measles virus RNA-dependent RNA 
polymerase complex activity: Synthesis and in vitro evaluation. Bioorg Med Chem Lett, 
2007. 17(18): p. 5199-203. 
31. White, L.K., et al., Nonnucleoside inhibitor of measles virus RNA-dependent RNA 
polymerase complex activity. Antimicrob Agents Chemother, 2007. 51(7): p. 2293-303. 
32. Krumm, S.A., et al., An orally available, small-molecule polymerase inhibitor shows 
efficacy against a lethal morbillivirus infection in a large animal model. Sci Transl Med, 
2014. 6(232): p. 232ra52. 
33. Mathieu, C., et al., Prevention of measles virus infection by intranasal delivery of fusion 
inhibitor peptides. J Virol, 2015. 89(2): p. 1143-55. 
34. Plemper, R.K. and R.M. Cox, Biology must develop herd immunity against bad-actor 
molecules. PLoS Pathog, 2018. 14(6): p. e1007038. 
35. Sourimant, J. and R.K. Plemper, Organization, Function, and Therapeutic Targeting of the 
Morbillivirus RNA-Dependent RNA Polymerase Complex. Viruses, 2016. 8(9). 
92 
36. Parks, R.A.L.a.G.D., Paramyxoviridae, in Fields Virology, D.M.K.a.P.M. Howley, Editor. 
2013, Lippincott williams and wilkins: Philadelphia PA. p. 957-995. 
37. White, J.M., et al., Structures and mechanisms of viral membrane fusion proteins: 
multiple variations on a common theme. Crit Rev Biochem Mol Biol, 2008. 43(3): p. 189-
219. 
38. Hashiguchi, T., et al., Crystal structure of measles virus hemagglutinin provides insight 
into effective vaccines. Proc Natl Acad Sci U S A, 2007. 104(49): p. 19535-40. 
39. Plemper, R.K., A.L. Hammond, and R. Cattaneo, Measles virus envelope glycoproteins 
hetero-oligomerize in the endoplasmic reticulum. J Biol Chem, 2001. 276(47): p. 44239-
46. 
40. Plemper, R.K., M.A. Brindley, and R.M. Iorio, Structural and mechanistic studies of 
measles virus illuminate paramyxovirus entry. PLoS Pathog, 2011. 7(6): p. e1002058. 
41. Brindley, M.A., S. Chaudhury, and R.K. Plemper, Measles virus glycoprotein complexes 
preassemble intracellularly and relax during transport to the cell surface in preparation 
for fusion. J Virol, 2015. 89(2): p. 1230-41. 
42. Hsu, E.C., et al., CDw150(SLAM) is a receptor for a lymphotropic strain of measles virus 
and may account for the immunosuppressive properties of this virus. Virology, 2001. 
279(1): p. 9-21. 
43. Schneider-Schaulies, J., et al., Receptor usage and differential downregulation of CD46 
by measles virus wild-type and vaccine strains. Proc Natl Acad Sci U S A, 1995. 92(9): p. 
3943-7. 
44. Manchester, M., et al., Multiple isoforms of CD46 (membrane cofactor protein) serve as 
receptors for measles virus. Proc Natl Acad Sci U S A, 1994. 91(6): p. 2161-5. 
45. Baker, K.A., et al., Structural basis for paramyxovirus-mediated membrane fusion. Mol 
Cell, 1999. 3(3): p. 309-19. 
46. Plemper, R.K. and R.W. Compans, Mutations in the putative HR-C region of the measles 
virus F2 glycoprotein modulate syncytium formation. J Virol, 2003. 77(7): p. 4181-90. 
47. Brindley, M.A., et al., A stabilized headless measles virus attachment protein stalk 
efficiently triggers membrane fusion. J. Virol., 2013. 87: p. 11693-11703. 
48. Plumet, S., W.P. Duprex, and D. Gerlier, Dynamics of viral RNA synthesis during measles 
virus infection. J Virol, 2005. 79(11): p. 6900-8. 
49. Salditt, A., et al., Measles virus M protein-driven particle production does not involve the 
endosomal sorting complex required for transport (ESCRT) system. J Gen Virol, 2010. 
91(Pt 6): p. 1464-72. 
50. Harrison, M.S., T. Sakaguchi, and A.P. Schmitt, Paramyxovirus assembly and budding: 
building particles that transmit infections. Int J Biochem Cell Biol, 2010. 42(9): p. 1416-
29. 
51. Votteler, J. and W.I. Sundquist, Virus budding and the ESCRT pathway. Cell Host 
Microbe, 2013. 14(3): p. 232-41. 
52. Fearns, R. and R.K. Plemper, Polymerases of paramyxoviruses and pneumoviruses. Virus 
Res, 2017. 234: p. 87-102. 
53. Cattaneo, R., et al., Altered transcription of a defective measles virus genome derived 
from a diseased human brain. EMBO J, 1987. 6(3): p. 681-8. 
93 
54. Harty, R.N. and P. Palese, Measles virus phosphoprotein (P) requires the NH2- and 
COOH-terminal domains for interactions with the nucleoprotein (N) but only the COOH 
terminus for interactions with itself. J Gen Virol, 1995. 76 ( Pt 11): p. 2863-7. 
55. Kolakofsky, D., et al., Viral DNA polymerase scanning and the gymnastics of Sendai virus 
RNA synthesis. Virology, 2004. 318(2): p. 463-73. 
56. Guryanov, S.G., et al., Crystal Structure of the Measles Virus Nucleoprotein Core in 
Complex with an N-Terminal Region of Phosphoprotein. J Virol, 2015. 90(6): p. 2849-57. 
57. Gutsche, I., et al., Near-atomic cryo-EM structure of the helical measles virus 
nucleocapsid. Science, 2015. 348(6235): p. 704-707. 
58. Jensen, M.R., et al., Intrinsic disorder in measles virus nucleocapsids. Proc Natl Acad Sci U 
S A, 2011. 108(24): p. 9839-44. 
59. Bourhis, J.M., et al., The intrinsically disordered C-terminal domain of the measles virus 
nucleoprotein interacts with the C-terminal domain of the phosphoprotein via two 
distinct sites and remains predominantly unfolded. Protein Science, 2005. 14(8): p. 1975-
1992. 
60. Karlin, D., S. Longhi, and B. Canard, Substitution of two residues in the measles virus 
nucleoprotein results in an impaired self-association. Virology, 2002. 302(2): p. 420-32. 
61. Bankamp, B., et al., Domains of the measles virus N protein required for binding to P 
protein and self-assembly. Virology, 1996. 216(1): p. 272-7. 
62. Communie, G., et al., Atomic resolution description of the interaction between the 
nucleoprotein and phosphoprotein of Hendra virus. PLoS Pathog, 2013. 9(9): p. 
e1003631. 
63. Schoehn, G., et al., The 12 A structure of trypsin-treated measles virus N-RNA. J Mol Biol, 
2004. 339(2): p. 301-12. 
64. Shu, Y., et al., Plasticity in structural and functional interactions between the 
phosphoprotein and nucleoprotein of measles virus. J Biol Chem, 2012. 287(15): p. 
11951-67. 
65. Wang, Y., et al., Multiscaled exploration of coupled folding and binding of an intrinsically 
disordered molecular recognition element in measles virus nucleoprotein. Proc Natl Acad 
Sci U S A, 2013. 110(40): p. E3743-52. 
66. Brunel, J., et al., Sequence of events in measles virus replication: role of phosphoprotein-
nucleocapsid interactions. J Virol, 2014. 88(18): p. 10851-63. 
67. Bloyet, L.M., et al., Modulation of Re-initiation of Measles Virus Transcription at 
Intergenic Regions by PXD to NTAIL Binding Strength. PLoS Pathog, 2016. 12(12): p. 
e1006058. 
68. Gruet, A., et al., Dissecting partner recognition by an intrinsically disordered protein 
using descriptive random mutagenesis. J Mol Biol, 2013. 425(18): p. 3495-509. 
69. Communie, G., et al., Intrinsically disordered proteins implicated in paramyxoviral 
replication machinery. Curr Opin Virol, 2014. 5: p. 72-81. 
70. Bonetti, D., et al., Analyzing the Folding and Binding Steps of an Intrinsically Disordered 
Protein by Protein Engineering. Biochemistry, 2017. 56(29): p. 3780-3786. 
71. Krumm, S.A., M. Takeda, and R.K. Plemper, The Measles Virus Nucleocapsid Protein Tail 
Domain Is Dispensable for Viral Polymerase Recruitment and Activity. Journal of 
Biological Chemistry, 2013. 288(41): p. 29943-29953. 
94 
72. Thakkar, V.D., et al., The Unstructured Paramyxovirus Nucleocapsid Protein Tail Domain 
Modulates Viral Pathogenesis through Regulation of Transcriptase Activity. J Virol, 2018. 
92(8). 
73. Cox, R.M., et al., The structurally disordered paramyxovirus nucleocapsid protein tail 
domain is a regulator of the mRNA transcription gradient. Sci Adv, 2017. 3(2): p. 
e1602350. 
74. Cevik, B., et al., The phosphoprotein (P) and L binding sites reside in the N-terminus of 
the L subunit of the measles virus RNA polymerase. Virology, 2004. 327(2): p. 297-306. 
75. Horikami, S.M., et al., An amino-proximal domain of the L protein binds to the P protein 
in the measles virus RNA polymerase complex. Virology, 1994. 205(2): p. 540-5. 
76. Malur, A.G., et al., Analysis of the mutations in the active site of the RNA-dependent RNA 
polymerase of human parainfluenza virus type 3 (HPIV3). Gene Expr, 2002. 10(3): p. 93-
100. 
77. Gopinath, M. and M.S. Shaila, Evidence for N(7) guanine methyl transferase activity 
encoded within the modular domain of RNA-dependent RNA polymerase L of a 
Morbillivirus. Virus Genes, 2015. 51(3): p. 356-60. 
78. Nishio, M., et al., Human parainfluenza virus type 2 L protein regions required for 
interaction with other viral proteins and mRNA capping. J Virol, 2011. 85(2): p. 725-32. 
79. Duprex, W.P., F.M. Collins, and B.K. Rima, Modulating the function of the measles virus 
RNA-dependent RNA polymerase by insertion of green fluorescent protein into the open 
reading frame. Journal of Virology, 2002. 76(14): p. 7322-7328. 
80. Dochow, M., et al., Independent structural domains in paramyxovirus polymerase 
protein. J Biol Chem, 2012. 287(9): p. 6878-91. 
81. Gilman, M.S.A., et al., Structure of the Respiratory Syncytial Virus Polymerase Complex. 
Cell, 2019. 179(1): p. 193-204 e14. 
82. Liang, B., et al., Structure of the L Protein of Vesicular Stomatitis Virus from Electron 
Cryomicroscopy. Cell, 2015. 162(2): p. 314-327. 
83. Tao, Y., et al., RNA synthesis in a cage--structural studies of reovirus polymerase 
lambda3. Cell, 2002. 111(5): p. 733-45. 
84. Rahmeh, A.A., et al., Critical phosphoprotein elements that regulate polymerase 
architecture and function in vesicular stomatitis virus. Proc Natl Acad Sci U S A, 2012. 
109(36): p. 14628-33. 
85. Guryanov, S.G., et al., Crystal Structure of the Measles Virus Nucleoprotein Core in 
Complex with an N-Terminal Region of Phosphoprotein. Journal of Virology, 2016. 90(6): 
p. 2849-2857. 
86. Communie, G., et al., Structure of the tetramerization domain of measles virus 
phosphoprotein. J Virol, 2013. 87(12): p. 7166-9. 
87. Johansson, K., et al., Crystal structure of the measles virus phosphoprotein domain 
responsible for the induced folding of the C-terminal domain of the nucleoprotein. J Biol 
Chem, 2003. 278(45): p. 44567-73. 
88. Karlin, D. and R. Belshaw, Detecting remote sequence homology in disordered proteins: 
discovery of conserved motifs in the N-termini of Mononegavirales phosphoproteins. 
PLoS One, 2012. 7(3): p. e31719. 
95 
89. Yabukarski, F., et al., Structure of Nipah virus unassembled nucleoprotein in complex 
with its viral chaperone. Nat Struct Mol Biol, 2014. 21(9): p. 754-9. 
90. Leyrat, C., et al., Structure of the vesicular stomatitis virus N(0)-P complex. PLoS Pathog, 
2011. 7(9): p. e1002248. 
91. Bruhn, J.F., et al., Crystal structure of the nipah virus phosphoprotein tetramerization 
domain. J Virol, 2014. 88(1): p. 758-62. 
92. Bruhn, J.F., et al., A Conserved Basic Patch and Central Kink in the Nipah Virus 
Phosphoprotein Multimerization Domain Are Essential for Polymerase Function. 
Structure, 2019. 
93. Bloyet, L.M., et al., Regulation of measles virus gene expression by P protein coiled-coil 
properties. Sci Adv, 2019. 5(5): p. eaaw3702. 
94. Blocquel, D., et al., Coiled-coil deformations in crystal structures: the measles virus 
phosphoprotein multimerization domain as an illustrative example. Acta 
Crystallographica. Section D, Biological Crystallography, 2014. 70(Pt 6): p. 1589-1603. 
95. Dosnon, M., et al., Demonstration of a folding after binding mechanism in the 
recognition between the measles virus NTAIL and X domains. ACS Chem Biol, 2015. 
10(3): p. 795-802. 
96. Kingston, R.L., et al., Structural basis for the attachment of a paramyxoviral polymerase 
to its template. Proc Natl Acad Sci U S A, 2004. 101(22): p. 8301-6. 
97. Gruet, A., et al., Fuzzy regions in an intrinsically disordered protein impair protein-
protein interactions. FEBS J, 2016. 283(4): p. 576-94. 
98. Gely, S., et al., Solution structure of the C-terminal X domain of the measles virus 
phosphoprotein and interaction with the intrinsically disordered C-terminal domain of 
the nucleoprotein. Journal of Molecular Recognition, 2010. 23(5): p. 435-447. 
99. Liston, P., C. Diflumeri, and D.J. Briedis, Protein Interactions Entered into by the Measles-
Virus P-Proteins, V-Proteins, and C-Proteins. Virus Research, 1995. 38(2-3): p. 241-259. 
100. Chattopadhyay, A. and M.S. Shaila, Rinderpest virus RNA polymerase subunits: Mapping 
of mutual interacting domains on the Large protein L and Phosphoprotein P. Virus 
Genes, 2004. 28(2): p. 169-178. 
101. Saikia, P. and M.S. Shaila, Identification of functional domains of phosphoproteins of two 
morbilliviruses using chimeric proteins. Virus Genes, 2008. 37(1): p. 1-8. 
102. Bloyet, L.M., et al., HSP90 Chaperoning in Addition to Phosphoprotein Required for 
Folding but Not for Supporting Enzymatic Activities of Measles and Nipah Virus L 
Polymerases. J Virol, 2016. 90(15): p. 6642-6656. 
103. Geller, R., R. Andino, and J. Frydman, Hsp90 inhibitors exhibit resistance-free antiviral 
activity against respiratory syncytial virus. PLoS One, 2013. 8(2): p. e56762. 
104. Smith, D.R., et al., Inhibition of heat-shock protein 90 reduces Ebola virus replication. 
Antiviral Res, 2010. 87(2): p. 187-94. 
105. Connor, J.H., et al., Antiviral activity and RNA polymerase degradation following Hsp90 
inhibition in a range of negative strand viruses. Virology, 2007. 362(1): p. 109-19. 
106. Krumm, S.A., M. Takeda, and R.K. Plemper, The measles virus nucleocapsid protein tail 
domain is dispensable for viral polymerase recruitment and activity. J Biol Chem, 2013. 
288(41): p. 29943-53. 
96 
107. Doyle, J., et al., Two domains that control prefusion stability and transport competence 
of the measles virus fusion protein. J Virol, 2006. 80(3): p. 1524-36. 
108. Chan, W.M., et al., How many mutant p53 molecules are needed to inactivate a 
tetramer? Mol Cell Biol, 2004. 24(8): p. 3536-51. 
109. Rima, B.K. and W.P. Duprex, New concepts in measles virus replication: getting in and 
out in vivo and modulating the host cell environment. Virus Res, 2011. 162(1-2): p. 47-
62. 
110. Blocquel, D., et al., Compaction and binding properties of the intrinsically disordered C-
terminal domain of Henipavirus nucleoprotein as unveiled by deletion studies. Mol 
Biosyst, 2012. 8(1): p. 392-410. 
111. Harbury, P.B., et al., A switch between two-, three-, and four-stranded coiled coils in 
GCN4 leucine zipper mutants. Science, 1993. 262(5138): p. 1401-7. 
112. Bloyet, L.M., et al., Modulation of Re-initiation of Measles Virus Transcription at 
Intergenic Regions by P-XD to N-TAIL Binding Strength. Plos Pathogens, 2016. 12(12). 
113. Radecke, F., et al., Rescue of measles viruses from cloned DNA. EMBO J, 1995. 14(23): p. 
5773-84. 
114. Schrag, S.J., P.A. Rota, and W.J. Bellini, Spontaneous mutation rate of measles virus: 
direct estimation based on mutations conferring monoclonal antibody resistance. J Virol, 
1999. 73(1): p. 51-4. 
115. Kolakofsky, D., Paramyxovirus RNA synthesis, mRNA editing, and genome hexamer 
phase: A review. Virology, 2016. 498: p. 94-98. 
116. Kolakofsky, D., et al., Viral RNA polymerase scanning and the gymnastics of Sendai virus 
RNA synthesis. Virology, 2004. 318(2): p. 463-473. 
117. Morin, B., et al., The polymerase of negative-stranded RNA viruses. Curr Opin Virol, 
2013. 3(2): p. 103-10. 
118. Longhi, S., et al., How order and disorder within paramyxoviral nucleoproteins and 
phosphoproteins orchestrate the molecular interplay of transcription and replication. 
Cellular and Molecular Life Sciences, 2017. 74(17): p. 3091-3118. 
119. World Health, O., Rabies vaccines: WHO position paper, April 2018 - Recommendations. 
Vaccine, 2018. 36(37): p. 5500-5503. 
120. Gillet, J.P., P. Derer, and H. Tsiang, Axonal transport of rabies virus in the central nervous 
system of the rat. J Neuropathol Exp Neurol, 1986. 45(6): p. 619-34. 
121. Singh, R., et al., Rabies - epidemiology, pathogenesis, public health concerns and 
advances in diagnosis and control: a comprehensive review. Vet Q, 2017. 37(1): p. 212-
251. 
122. Shlim, D.R., Preventing rabies: the new WHO recommendations and their impact on 
travel medicine practice. J Travel Med, 2018. 25(1). 
123. Tawanwongsri, W. and P. Wattanakrai, Serum Sickness after Equine Rabies 
Immunoglobulin in Identical Male Twins: Two Case Reports. Case Rep Dermatol, 2019. 
11(1): p. 40-47. 
124. Sirikun, J., et al., Immunogenic response in obese patients undergoing rabies post-
exposure prophylaxis with combined equine rabies immunoglobulin and rabies 
vaccination. Vaccine, 2018. 36(2): p. 285-291. 
97 
125. Lang, J., et al., Evaluation of the safety, immunogenicity, and pharmacokinetic profile of 
a new, highly purified, heat-treated equine rabies immunoglobulin, administered either 
alone or in association with a purified, Vero-cell rabies vaccine. Acta Trop, 1998. 70(3): p. 
317-33. 
126. Badrane, H., et al., Evidence of two Lyssavirus phylogroups with distinct pathogenicity 
and immunogenicity. J Virol, 2001. 75(7): p. 3268-76. 
127. Du Pont, V., R.K. Plemper, and M.J. Schnell, Status of antiviral therapeutics against 
rabies virus and related emerging lyssaviruses. Curr Opin Virol, 2019. 35: p. 1-13. 
128. Douglas S. Lyles, I.V.K., and Charles E. Rupprecht, Rhabdoviridae, in Fields Virology, 
a.P.M.H. David M. Knipe, Editor. 2013, Lippincott Williams and Wilkens: Philadelphia, 
PA. p. 885-922. 
129. Ge, P., et al., Cryo-EM model of the bullet-shaped vesicular stomatitis virus. Science, 
2010. 327(5966): p. 689-93. 
130. Guo, Y., et al., Early events in rabies virus infection-Attachment, entry, and intracellular 
trafficking. Virus Res, 2019. 263: p. 217-225. 
131. Lafon, M., Rabies virus receptors. J Neurovirol, 2005. 11(1): p. 82-7. 
132. Piccinotti, S. and S.P. Whelan, Rabies Internalizes into Primary Peripheral Neurons via 
Clathrin Coated Pits and Requires Fusion at the Cell Body. PLoS Pathog, 2016. 12(7): p. 
e1005753. 
133. Piccinotti, S., T. Kirchhausen, and S.P. Whelan, Uptake of rabies virus into epithelial cells 
by clathrin-mediated endocytosis depends upon actin. J Virol, 2013. 87(21): p. 11637-47. 
134. Gaudin, Y., et al., Low-pH conformational changes of rabies virus glycoprotein and their 
role in membrane fusion. J Virol, 1993. 67(3): p. 1365-72. 
135. Gaudin, Y., et al., Reversible conformational changes and fusion activity of rabies virus 
glycoprotein. J Virol, 1991. 65(9): p. 4853-9. 
136. Miyamoto, K. and S. Matsumoto, The nature of the Negri body. J Cell Biol, 1965. 27(3): p. 
677-82. 
137. Covell, W.P. and W.B. Danks, Studies on the Nature of the Negri Body. Am J Pathol, 1932. 
8(5): p. 557-572 3. 
138. Finke, S., J.H. Cox, and K.K. Conzelmann, Differential transcription attenuation of rabies 
virus genes by intergenic regions: generation of recombinant viruses overexpressing the 
polymerase gene. J Virol, 2000. 74(16): p. 7261-9. 
139. Wu, X., et al., Both viral transcription and replication are reduced when the rabies virus 
nucleoprotein is not phosphorylated. J Virol, 2002. 76(9): p. 4153-61. 
140. Yang, J., et al., Phosphorylation of rabies virus nucleoprotein regulates viral RNA 
transcription and replication by modulating leader RNA encapsidation. J Virol, 1999. 
73(2): p. 1661-4. 
141. Finke, S. and K.K. Conzelmann, Dissociation of rabies virus matrix protein functions in 
regulation of viral RNA synthesis and virus assembly. J Virol, 2003. 77(22): p. 12074-82. 
142. Finke, S., R. Mueller-Waldeck, and K.K. Conzelmann, Rabies virus matrix protein 
regulates the balance of virus transcription and replication. J Gen Virol, 2003. 84(Pt 6): p. 
1613-21. 
143. Mebatsion, T., M. Konig, and K.K. Conzelmann, Budding of rabies virus particles in the 
absence of the spike glycoprotein. Cell, 1996. 84(6): p. 941-51. 
98 
144. Willoughby, R.E., Jr., et al., Survival after treatment of rabies with induction of coma. N 
Engl J Med, 2005. 352(24): p. 2508-14. 
145. Lampejo, T., et al., Caring for a patient with rabies: implications of the Milwaukee 
protocol for infection control and public health measures. J Hosp Infect, 2017. 96(4): p. 
385-391. 
146. Zeiler, F.A. and A.C. Jackson, Critical Appraisal of the Milwaukee Protocol for Rabies: This 
Failed Approach Should Be Abandoned. Can J Neurol Sci, 2016. 43(1): p. 44-51. 
147. Wilde, H. and T. Hemachudha, The "Milwaukee protocol" for treatment of human rabies 
is no longer valid. Pediatr Infect Dis J, 2015. 34(6): p. 678-9. 
148. Aramburo, A., et al., Failure of the Milwaukee protocol in a child with rabies. Clin Infect 
Dis, 2011. 53(6): p. 572-4. 
149. Rubin, J., et al., Applying the Milwaukee protocol to treat canine rabies in Equatorial 
Guinea. Scand J Infect Dis, 2009. 41(5): p. 372-5. 
150. Crance, J.M., et al., Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral 
compounds active against pathogenic flaviviruses. Antiviral Res, 2003. 58(1): p. 73-9. 
151. Enria, D.A. and J.I. Maiztegui, Antiviral treatment of Argentine hemorrhagic fever. 
Antiviral Res, 1994. 23(1): p. 23-31. 
152. Hosoya, M., et al., High-dose intravenous ribavirin therapy for subacute sclerosing 
panencephalitis. Antimicrob Agents Chemother, 2001. 45(3): p. 943-5. 
153. Huggins, J.W., R.K. Robins, and P.G. Canonico, Synergistic antiviral effects of ribavirin 
and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, 
bunyaviruses, and arenaviruses. Antimicrob Agents Chemother, 1984. 26(4): p. 476-80. 
154. Jordan, I., et al., Ribavirin inhibits West Nile virus replication and cytopathic effect in 
neural cells. J Infect Dis, 2000. 182(4): p. 1214-7. 
155. Kumar, R., et al., Randomized, controlled trial of oral ribavirin for Japanese encephalitis 
in children in Uttar Pradesh, India. Clin Infect Dis, 2009. 48(4): p. 400-6. 
156. Carrillo-Bustamante, P., et al., Determining Ribavirin's mechanism of action against 
Lassa virus infection. Sci Rep, 2017. 7(1): p. 11693. 
157. Lau, J.Y., et al., Mechanism of action of ribavirin in the combination treatment of chronic 
HCV infection. Hepatology, 2002. 35(5): p. 1002-9. 
158. Leyssen, P., et al., The predominant mechanism by which ribavirin exerts its antiviral 
activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP 
dehydrogenase. J Virol, 2005. 79(3): p. 1943-7. 
159. Colombo, G., et al., Brain distribution of ribavirin after intranasal administration. 
Antiviral Res, 2011. 92(3): p. 408-14. 
160. Warrell, M.J., et al., Failure of interferon alfa and tribavirin in rabies encephalitis. BMJ, 
1989. 299(6703): p. 830-3. 
161. Crumpacker, C., et al., Ribavirin enters cerebrospinal fluid. Lancet, 1986. 2(8497): p. 45-
6. 
162. Marschalek, A., L. Drechsel, and K.K. Conzelmann, The importance of being short: the 
role of rabies virus phosphoprotein isoforms assessed by differential IRES translation 
initiation. Eur J Cell Biol, 2012. 91(1): p. 17-23. 
99 
163. Lockhart, B.P., N. Tordo, and H. Tsiang, Inhibition of rabies virus transcription in rat 
cortical neurons with the dissociative anesthetic ketamine. Antimicrob Agents 
Chemother, 1992. 36(8): p. 1750-5. 
164. Benet, L.Z., et al., BDDCS, the Rule of 5 and drugability. Adv Drug Deliv Rev, 2016. 101: p. 
89-98. 
165. Chavez, J.H., et al., Evaluation of antiviral activity of phenolic compounds and derivatives 
against rabies virus. Vet Microbiol, 2006. 116(1-3): p. 53-9. 
166. Wu, Y.H., et al., Structure Properties and Mechanisms of Action of Naturally Originated 
Phenolic Acids and Their Derivatives against Human Viral Infections. Curr Med Chem, 
2017. 24(38): p. 4279-4302. 
167. Lingappa, U.F., et al., Host-rabies virus protein-protein interactions as druggable antiviral 
targets. Proc Natl Acad Sci U S A, 2013. 110(10): p. E861-8. 
168. Marosi, A., et al., Evaluation of in vitro inhibitory potential of type-I interferons and 
different antiviral compounds on rabies virus replication. Vaccine, 2018. 
169. Han, Z., et al., Small-molecule probes targeting the viral PPxY-host Nedd4 interface block 
egress of a broad range of RNA viruses. J Virol, 2014. 88(13): p. 7294-306. 
170. Appolinario, C.M. and A.C. Jackson, Antiviral therapy for human rabies. Antivir Ther, 
2015. 20(1): p. 1-10. 
171. Jochmans, D. and J. Neyts, The path towards effective antivirals against rabies. Vaccine, 
2019. 37(33): p. 4660-4662. 
172. Marosi, A., et al., Combination therapy of rabies-infected mice with inhibitors of pro-
inflammatory host response, antiviral compounds and human rabies immunoglobulin. 
Vaccine, 2019. 37(33): p. 4724-4735. 
173. Randrup Hansen, C., et al., Effects and Side Effects of Using Sorafenib and Sunitinib in the 
Treatment of Metastatic Renal Cell Carcinoma. Int J Mol Sci, 2017. 18(2). 
174. Gole, P., et al., Side effects of Sorafenib and sunitinib: A new concern for dermatologist 
and oncologist. Indian Dermatol Online J, 2014. 5(1): p. 89-91. 
175. Wolf, G., [Comments on the article "Cutaneous side effects of the multikinase inhibitors 
sorafenib and sunitinib"]. Hautarzt, 2011. 62(7): p. 560; author reply 561-4. 
176. Wollenberg, A., M. Staehler, and T. Eames, [Cutaneous side effects of the multikinase 
inhibitors sorafenib and sunitinib]. Hautarzt, 2010. 61(8): p. 662-7. 
177. Autier, J., et al., [Cutaneous side effects of sorafenib and sunitinib]. Ann Dermatol 
Venereol, 2008. 135(2): p. 148-53; quiz 147, 154. 
178. Jackson, A.C., Is minocycline useful for therapy of acute viral encephalitis? Antiviral Res, 
2012. 95(3): p. 242-4. 
179. Zink, M.C., et al., Neuroprotective and anti-human immunodeficiency virus activity of 
minocycline. JAMA, 2005. 293(16): p. 2003-11. 
180. Jackson, A.C., et al., Therapy with minocycline aggravates experimental rabies in mice. J 
Virol, 2007. 81(12): p. 6248-53. 
181. Yang, Y.J., et al., Small interfering RNAs targeting the rabies virus nucleoprotein gene. 
Virus Res, 2012. 169(1): p. 169-74. 
182. Gupta, P.K., et al., Intracerebral delivery of small interfering RNAs (siRNAs) using 
adenoviral vector protects mice against lethal peripheral rabies challenge. Virus Res, 
2012. 163(1): p. 11-8. 
100 
183. DeVincenzo, J., et al., Evaluation of the safety, tolerability and pharmacokinetics of ALN-
RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus 
(RSV). Antiviral Res, 2008. 77(3): p. 225-31. 
184. Ferreira, H.L., et al., Inhibition of avian metapneumovirus (AMPV) replication by RNA 
interference targeting nucleoprotein gene (N) in cultured cells. Antiviral Res, 2007. 74(1): 
p. 77-81. 
185. Lu, L., Y. Ho, and J. Kwang, Suppression of porcine arterivirus replication by baculovirus-
delivered shRNA targeting nucleoprotein. Biochem Biophys Res Commun, 2006. 340(4): 
p. 1178-83. 
186. Real, E., et al., Antiviral drug discovery strategy using combinatorial libraries of 
structurally constrained peptides. J Virol, 2004. 78(14): p. 7410-7. 
187. Castel, G., et al., Peptides that mimic the amino-terminal end of the rabies virus 
phosphoprotein have antiviral activity. J Virol, 2009. 83(20): p. 10808-20. 
188. Papaneri, A.B., et al., Alanine scanning of the rabies virus glycoprotein antigenic site III 
using recombinant rabies virus: implication for post-exposure treatment. Vaccine, 2013. 
31(49): p. 5897-902. 
189. Holmes, E.C., et al., Genetic constraints and the adaptive evolution of rabies virus in 
nature. Virology, 2002. 292(2): p. 247-57. 
190. Sakamoto, S., et al., Studies on the structures and antigenic properties of rabies virus 
glycoprotein analogues produced in yeast cells. Vaccine, 1999. 17(3): p. 205-18. 
191. Roche, S., et al., Structures of vesicular stomatitis virus glycoprotein: membrane fusion 
revisited. Cell Mol Life Sci, 2008. 65(11): p. 1716-28. 
192. Grill, A.K., Approach to management of suspected rabies exposures: what primary care 
physicians need to know. Can Fam Physician, 2009. 55(3): p. 247-51. 
193. Lentz, T.L., E. Hawrot, and P.T. Wilson, Synthetic peptides corresponding to sequences of 
snake venom neurotoxins and rabies virus glycoprotein bind to the nicotinic acetylcholine 
receptor. Proteins, 1987. 2(4): p. 298-307. 
194. Evans, J.S., et al., Antigenic site changes in the rabies virus glycoprotein dictates 
functionality and neutralizing capability against divergent lyssaviruses. J Gen Virol, 2018. 
99(2): p. 169-180. 
195. Sun, L., et al., [Generation of Human ScFv Antibodies for Antigenic Site III of Rabies Virus 
Glycoprotein from Antibody-phage Libraries by Chain Shuffling]. Bing Du Xue Bao, 2016. 
32(4): p. 393-8. 
196. Fallahi, F., A.I. Wandeler, and S.A. Nadin-Davis, Characterization of epitopes on the 
rabies virus glycoprotein by selection and analysis of escape mutants. Virus Res, 2016. 
220: p. 161-71. 
197. Kankanamge, P.J., et al., Mapping of the low pH-sensitive conformational epitope of 
rabies virus glycoprotein recognized by a monoclonal antibody #1-30-44. Microbiol 
Immunol, 2003. 47(7): p. 507-19. 
198. Schnell, M.J. and K.K. Conzelmann, Polymerase activity of in vitro mutated rabies virus L 
protein. Virology, 1995. 214(2): p. 522-30. 
199. Campbell, J.B., et al., The inhibition of rabies virus by arabinosyl cytosine. Studies on the 
mechanism and specificity of action. Virology, 1968. 34(4): p. 701-8. 
101 
200. Harmon, M.W. and B. Janis, Effects of cytosine arabinoside, adenine arabinoside, and 6-
azauridine on rabies virus in vitro and in vivo. J Infect Dis, 1976. 133(1): p. 7-13. 
201. Sodja, I. and A. Holy, Effect of 9-(S)-(2,3-dihydroxypropyl)adenine on experimental rabies 
infection in laboratory mice. Acta Virol, 1980. 24(5): p. 317-24. 
202. Banyard, A.C., et al., Re-evaluating the effect of Favipiravir treatment on rabies virus 
infection. Vaccine, 2019. 37(33): p. 4686-4693. 
203. Yamada, K., et al., Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis. J 
Infect Dis, 2016. 213(8): p. 1253-61. 
204. Poch, O., et al., Sequence comparison of five polymerases (L proteins) of unsegmented 
negative-strand RNA viruses: theoretical assignment of functional domains. J Gen Virol, 
1990. 71 ( Pt 5): p. 1153-62. 
205. Albertini, A.A., et al., Structural aspects of rabies virus replication. Cell Mol Life Sci, 2008. 
65(2): p. 282-94. 
206. Li, J., J.T. Wang, and S.P. Whelan, A unique strategy for mRNA cap methylation used by 
vesicular stomatitis virus. Proc Natl Acad Sci U S A, 2006. 103(22): p. 8493-8. 
207. Li, J., E.C. Fontaine-Rodriguez, and S.P. Whelan, Amino acid residues within conserved 
domain VI of the vesicular stomatitis virus large polymerase protein essential for mRNA 
cap methyltransferase activity. J Virol, 2005. 79(21): p. 13373-84. 
208. Hemachudha, T., et al., Failure of therapeutic coma and ketamine for therapy of human 
rabies. J Neurovirol, 2006. 12(5): p. 407-9. 
209. Anindita, P.D., et al., Ribavirin-related compounds exert in vitro inhibitory effects toward 
rabies virus. Antiviral Res, 2018. 154: p. 1-9. 
210. Banyard, A.C., et al., Re-evaluating the effect of Favipiravir treatment on rabies virus 
infection. Vaccine, 2017. 
211. Rose, J.K., Positive strands to the rescue again: a segmented negative-strand RNA virus 
derived from cloned cDNAs. Proc Natl Acad Sci U S A, 1996. 93(26): p. 14998-5000. 
212. Yan, D., et al., Dual myxovirus screen identifies a small-molecule agonist of the host 
antiviral response. J Virol, 2013. 87(20): p. 11076-87. 
213. Weisshaar, M., et al., Identification and Characterization of Influenza Virus Entry 
Inhibitors through Dual Myxovirus High-Throughput Screening. J Virol, 2016. 90(16): p. 
7368-7387. 
214. Krumm, S.A., et al., Potent host-directed small-molecule inhibitors of myxovirus RNA-
dependent RNA-polymerases. PLoS One, 2011. 6(5): p. e20069. 
215. Zhang, J.H., T.D. Chung, and K.R. Oldenburg, A Simple Statistical Parameter for Use in 
Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen, 1999. 
4(2): p. 67-73. 
216. Yan, X., et al., The rabies virus glycoprotein determines the distribution of different rabies 
virus strains in the brain. J Neurovirol, 2002. 8(4): p. 345-52. 
217. Ellison, J.A., et al., Multidisciplinary approach to epizootiology and pathogenesis of bat 
rabies viruses in the United States. Zoonoses Public Health, 2013. 60(1): p. 46-57. 
218. Reardon, T.R., et al., Rabies Virus CVS-N2c(DeltaG) Strain Enhances Retrograde Synaptic 
Transfer and Neuronal Viability. Neuron, 2016. 89(4): p. 711-24. 
219. Morimoto, K., et al., Rabies virus quasispecies: implications for pathogenesis. Proc Natl 
Acad Sci U S A, 1998. 95(6): p. 3152-6. 
102 
220. Yan, D., et al., Cross-resistance mechanism of respiratory syncytial virus against 
structurally diverse entry inhibitors. Proc Natl Acad Sci U S A, 2014. 111(33): p. E3441-9. 
221. Mackman, R.L., et al., Discovery of an oral respiratory syncytial virus (RSV) fusion 
inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study. J Med 
Chem, 2015. 58(4): p. 1630-43. 
222. Lama, Z., et al., Kinase inhibitors tyrphostin 9 and rottlerin block early steps of rabies 
virus cycle. Antiviral Res, 2019. 168: p. 51-60. 
223. Wirblich, C. and M.J. Schnell, Rabies virus (RV) glycoprotein expression levels are not 
critical for pathogenicity of RV. J Virol, 2011. 85(2): p. 697-704. 
224. Morimoto, K., et al., Reinvestigation of the role of the rabies virus glycoprotein in viral 
pathogenesis using a reverse genetics approach. J Neurovirol, 2000. 6(5): p. 373-81. 
225. Takayama-Ito, M., et al., Multiple amino acids in the glycoprotein of rabies virus are 
responsible for pathogenicity in adult mice. Virus Res, 2006. 115(2): p. 169-75. 
226. Perron, M., et al., GS-5806 Inhibits a Broad Range of Respiratory Syncytial Virus Clinical 
Isolates by Blocking the Virus-Cell Fusion Process. Antimicrob Agents Chemother, 2015. 
60(3): p. 1264-73. 
227. Hashiguchi, T., et al., Structures of the prefusion form of measles virus fusion protein in 
complex with inhibitors. Proc Natl Acad Sci U S A, 2018. 115(10): p. 2496-2501. 
228. Ozawa, T., Designing split reporter proteins for analytical tools. Anal Chim Acta, 2006. 
556(1): p. 58-68. 
229. Abrahamyan, L.G., et al., The cytoplasmic tail slows the folding of human 
immunodeficiency virus type 1 Env from a late prebundle configuration into the six-helix 
bundle. J Virol, 2005. 79(1): p. 106-15. 
230. Gaudin, Y., et al., Biological function of the low-pH, fusion-inactive conformation of 
rabies virus glycoprotein (G): G is transported in a fusion-inactive state-like 
conformation. J Virol, 1995. 69(9): p. 5528-34. 
231. Ilina, E.N., et al., Recombinant Monoclonal Antibodies for Rabies Post-exposure 
Prophylaxis. Biochemistry (Mosc), 2018. 83(1): p. 1-12. 
232. Sun, X., S. Belouzard, and G.R. Whittaker, Molecular architecture of the bipartite fusion 
loops of vesicular stomatitis virus glycoprotein G, a class III viral fusion protein. J Biol 
Chem, 2008. 283(10): p. 6418-27. 
233. Plattet, P., et al., Signal peptide and helical bundle domains of virulent canine distemper 
virus fusion protein restrict fusogenicity. J Virol, 2007. 81(20): p. 11413-25. 
234. Horvath, C.M. and R.A. Lamb, Studies on the fusion peptide of a paramyxovirus fusion 
glycoprotein: roles of conserved residues in cell fusion. J Virol, 1992. 66(4): p. 2443-55. 
235. Sergel, T.A., L.W. McGinnes, and T.G. Morrison, A single amino acid change in the 
Newcastle disease virus fusion protein alters the requirement for HN protein in fusion. J 
Virol, 2000. 74(11): p. 5101-7. 
236. Terrier, O., et al., Characterization of naturally occurring parainfluenza virus type 2 
(hPIV-2) variants. J Clin Virol, 2008. 43(1): p. 86-92. 
237. Fredericksen, B.L. and M.A. Whitt, Vesicular stomatitis virus glycoprotein mutations that 
affect membrane fusion activity and abolish virus infectivity. J Virol, 1995. 69(3): p. 1435-
43. 
103 
238. Martinez, I. and G.W. Wertz, Biological differences between vesicular stomatitis virus 
Indiana and New Jersey serotype glycoproteins: identification of amino acid residues 
modulating pH-dependent infectivity. J Virol, 2005. 79(6): p. 3578-85. 
239. Shakin-Eshleman, S.H., et al., N-linked glycosylation of rabies virus glycoprotein. 
Individual sequons differ in their glycosylation efficiencies and influence on cell surface 
expression. J Biol Chem, 1992. 267(15): p. 10690-8. 
240. Yamada, K., et al., Addition of a single N-glycan to street rabies virus glycoprotein 
enhances virus production. J Gen Virol, 2013. 94(Pt 2): p. 270-5. 
241. Yamada, K., K. Noguchi, and A. Nishizono, Characterization of street rabies virus variants 
with an additional N-glycan at position 247 in the glycoprotein. Arch Virol, 2014. 159(2): 
p. 207-16. 
242. Gaudin, Y., et al., Identification of amino acids controlling the low-pH-induced 
conformational change of rabies virus glycoprotein. J Virol, 1996. 70(11): p. 7371-8. 
 
 
 
  
104 
4 APPENDICES  
4.1 Appendix A Chapter 1 Results and Discussion Source 
 
 
 
RESEARCH ARTICLE
Bipartite interface of the measles virus
phosphoprotein X domain with the large
polymerase protein regulates viral
polymerase dynamics
Venice Du Pont1, Yi Jiang2, Richard K. PlemperID
1
1 Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, United States of America,
2 Department of Mathematics and Statistics, Georgia State University, Atlanta, Georgia, United States of
America
* rplemper@gsu.edu
Abstract
Measles virus (MeV) is a highly contagious, re-emerging, major human pathogen. Replica-
tion requires a viral RNA-dependent RNA polymerase (RdRP) consisting of the large (L)
polymerase protein complexed with the homo-tetrameric phosphoprotein (P). In addition, P
mediates interaction with the nucleoprotein (N)-encapsidated viral RNA genome. The nature
of the P:L interface and RdRP negotiation of the ribonucleoprotein template are poorly
understood. Based on biochemical interface mapping, swapping of the central P tetrameri-
zation domain (OD) for yeast GCN4, and functional assays, we demonstrate that the MeV
P-to-L interface is bipartite, comprising a coiled-coil microdomain proximal to the OD and an
unoccupied face of the triangular prism-shaped C-terminal P X-domain (P-XD), which is dis-
tinct from the known P-XD face that binds N-tail. Mixed null-mutant P tetramers regained L-
binding competence in a ratio-dependent manner and fully reclaimed bioactivity in minirepli-
con assays and recombinant MeV, demonstrating that the individual L-binding interface ele-
ments are physically and mechanistically distinct. P-XD binding competence to L and N was
likewise trans-complementable, which, combined with mathematical modeling, enabled the
mechanistic characterization of P through two- and stoichiometrically-controlled three-way
complementations. Only one each of the four XDs per P tetramer must be L or N binding-
competent for bioactivity, but interaction of the same P-XD with L and N was mutually exclu-
sive, and L binding superseded engaging N. Mixed P tetramers with a single, designated L
binding-competent P-XD caused significant RdRP hyperactivity, outlining a model of itera-
tive resolution and reformation of the P-XD:L interface regulating polymerase mobility.
Author summary
MeV belongs to the order of non-segmented negative polarity RNA viruses, which
includes devastating human pathogens. While all feature encapsidated RNA genomes and
P-L type polymerase complexes, insight into the intermolecular interactions within the
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Status of antiviral therapeutics against rabies virus and
related emerging lyssaviruses
Venice Du Pont1, Richard K Plemper1 and Matthias J Schnell2
Rabies virus (RABV) constitutes a major social and economic
burden associated with 60 000 deaths annually worldwide.
Although pre-exposure and post-exposure treatment options
are available, they are efficacious only when initiated before the
onset of clinical symptoms. Aggravating the problem, the
current RABV vaccine does not cross-protect against the
emerging zoonotic phylogroup II lyssaviruses. A requirement
for an uninterrupted cold chain and high cost of the
immunoglobulin component of rabies prophylaxis generate an
unmet need for the development of RABV-specific antivirals.
We discuss desirable anti-RABV drug profiles, past efforts to
address the problem and inhibitor candidates identified, and
examine how the rapidly expanding structural insight into RABV
protein organization has illuminated novel druggable target
candidates and paved the way to structure-aided drug
optimization. Special emphasis is given to the viral RNA-
dependent RNA polymerase complex as a promising target for
direct-acting broad-spectrum RABV inhibitors.
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Introduction
The devastating signs and symptoms of rabies disease have
been documented as far back as 2000 B.C. in the Eshnunna
tablets of Mesopotamia [1]. Even now, in the second
millennia A.D, rabies disease continues to be a social
and economic hardship with approximately 60 000 deaths
worldwide, nearly $8.6 billion in economic burden, and $1.5
billion spent on post-exposure prophylaxis treatment
(PEP) alone [2]. The causative agents, lyssaviruses, within
the Rhabdoviridae family, are characterized as zoonotic,
neurotropic negative-sense non-segmented RNA viruses.
Transmission of rabies virus (RABV) occurs typically
through the transfer of infectious saliva from the percuta-
neous bite of a mammal, usually a dog [2]. Through
axoplasmic transport, RABV enters the central nervous
system (CNS) where it begins to replicate, causing severe
neuronal dysfunction [3–5]. Rabies is vaccine-preventable
as well as treatable early after infection. After the onset of
clinical symptoms, however, almost all patients succumb to
the infection, progressing toward coma and ultimately
death [6!]. RABV’s ability to effectively subvert the host
immune system through evasion of TLR signaling, down-
regulation of IFN signaling, and prevention of adaptive
responses by maintaining lowered blood–brain barrier
(BBB) permeability, and induction of T-cell apoptosis
exemplifies why early intervention is critical [7,8,9!]. As
depicted in Figure 1, treatment of rabies consists of rabies
immune-globin (RIG) and four doses of the vaccine over a
four-week period. PEP is recommended for previously
vaccinated individuals as well, and consists of vaccine doses
on days 0 and 3. A single PEP regimen costs at least $3000 in
the United States [2]. This expense of rabies PEP is
predominantly due to the high cost of producing human
rabies immune-globin HRIG, a human plasma-based prod-
uct, with a relatively short shelf life and need for extensive
quality assurance [10]. A second contributor to the high
treatment cost is the requirement of four doses of rabies
vaccine, which typically costs $260 per dose in the USA and
Europe. In Africa and Asia, where 95% of rabies-related
deaths occur, PEP averages $40 and $49, respectively. This
expense is often out of reach in areas with a daily family
income of approximately $1–2. The number of people
worldwide that receive rabies PEP as well as the crippling
debt associated with it is estimated to reach a staggering
15 million annually [2]. Furthermore, the current vaccine is
likely ineffective against emerging zoonotic lyssaviruses of
phylogroup II such as Mokola (MOKV) and Lagos bat
viruses [11–15]. The high cost of HRIG and the current
vaccine, along with cold-chain requirements for both, pres-
ent an urgent and unmet clinical need for the development
of safe, cost-effective, efficacious, shelf-stable, and cross-
protective antivirals against lyssavirus phylogroups associ-
ated with human rabies disease. Antiviral compounds could
be used to replace the HRIG or other RIG component in
current rabies PEP (Table 1).
Lyssavirus virion organization
Lyssaviruses contain RNA genomes of approximately
12 kb. The virion of lyssaviruses, as with the other family
members of Rhabdoviridae, is characterized by a bullet-
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